<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Follow‐up strategies for patients treated for non‐metastatic colorectal cancer - Jeffery, M - 2019 | Cochrane Library</title> <meta content="Follow‐up strategies for patients treated for non‐metastatic colorectal cancer - Jeffery, M - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002200.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Follow‐up strategies for patients treated for non‐metastatic colorectal cancer - Jeffery, M - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002200.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002200.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Follow‐up strategies for patients treated for non‐metastatic colorectal cancer" name="citation_title"/> <meta content="Mark Jeffery" name="citation_author"/> <meta content="Christchurch Hospital" name="citation_author_institution"/> <meta content="mark.jeffery@cdhb.govt.nz" name="citation_author_email"/> <meta content="Brigid E Hickey" name="citation_author"/> <meta content="Phillip N Hider" name="citation_author"/> <meta content="University of Otago, Christchurch" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD002200.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002200.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002200.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002200.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Colorectal Neoplasms [*drug therapy, *surgery]; Disease‐Free Survival; Follow‐Up Studies; Neoplasm Recurrence, Local; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002200.pub4&amp;doi=10.1002/14651858.CD002200.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002200\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002200\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","ja","fa","fr","zh_HANS","de","ru","pt"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002200.pub4",title:"Follow\\u2010up strategies for patients treated for non\\u2010metastatic colorectal cancer",firstPublishedDate:"Sep 4, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Colorectal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002200.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002200.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002200.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002200.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002200.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002200.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002200.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002200.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002200.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002200.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7180 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002200.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/appendices#CD002200-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/table_n/CD002200StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/table_n/CD002200StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Follow‐up strategies for patients treated for non‐metastatic colorectal cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information#CD002200-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mark Jeffery</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information#CD002200-cr-0003">Brigid E Hickey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information#CD002200-cr-0004">Phillip N Hider</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information/en#CD002200-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002200.pub4">https://doi.org/10.1002/14651858.CD002200.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002200-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002200-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002200-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002200-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002200-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002200-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002200-abs-0001" lang="en"> <section id="CD002200-sec-0001"> <h3 class="title" id="CD002200-sec-0001">Background</h3> <p>This is the fourth update of a Cochrane Review first published in 2002 and last updated in 2016.<br/> It is common clinical practice to follow patients with colorectal cancer for several years following their curative surgery or adjuvant therapy, or both. Despite this widespread practice, there is considerable controversy about how often patients should be seen, what tests should be performed, and whether these varying strategies have any significant impact on patient outcomes. </p> </section> <section id="CD002200-sec-0002"> <h3 class="title" id="CD002200-sec-0002">Objectives</h3> <p>To assess the effect of follow‐up programmes (follow‐up versus no follow‐up, follow‐up strategies of varying intensity, and follow‐up in different healthcare settings) on overall survival for patients with colorectal cancer treated with curative intent. Secondary objectives are to assess relapse‐free survival, salvage surgery, interval recurrences, quality of life, and the harms and costs of surveillance and investigations. </p> </section> <section id="CD002200-sec-0003"> <h3 class="title" id="CD002200-sec-0003">Search methods</h3> <p>For this update, on 5 April 2109 we searched CENTRAL, MEDLINE, Embase, CINAHL, and Science Citation Index. We also searched reference lists of articles, and handsearched the Proceedings of the American Society for Radiation Oncology. In addition, we searched the following trials registries: ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. We contacted study authors. We applied no language or publication restrictions to the search strategies. </p> </section> <section id="CD002200-sec-0004"> <h3 class="title" id="CD002200-sec-0004">Selection criteria</h3> <p>We included only randomised controlled trials comparing different follow‐up strategies for participants with non‐metastatic colorectal cancer treated with curative intent. </p> </section> <section id="CD002200-sec-0005"> <h3 class="title" id="CD002200-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Two review authors independently determined study eligibility, performed data extraction, and assessed risk of bias and methodological quality. We used GRADE to assess evidence quality. </p> </section> <section id="CD002200-sec-0006"> <h3 class="title" id="CD002200-sec-0006">Main results</h3> <p>We identified 19 studies, which enrolled 13,216 participants (we included four new studies in this second update). Sixteen out of the 19 studies were eligible for quantitative synthesis. Although the studies varied in setting (general practitioner (GP)‐led, nurse‐led, or surgeon‐led) and 'intensity' of follow‐up, there was very little inconsistency in the results. </p> <p>Overall survival: we found intensive follow‐up made little or no difference (hazard ratio (HR) 0.91, 95% confidence interval (CI) 0.80 to 1.04: I² = 18%; high‐quality evidence). There were 1453 deaths among 12,528 participants in 15 studies. In absolute terms, the average effect of intensive follow‐up on overall survival was 24 fewer deaths per 1000 patients, but the true effect could lie between 60 fewer to 9 more per 1000 patients. </p> <p>Colorectal cancer‐specific survival: we found intensive follow‐up probably made little or no difference (HR 0.93, 95% CI 0.81 to 1.07: I² = 0%; moderate‐quality evidence). There were 925 colorectal cancer deaths among 11,771 participants enrolled in 11 studies. In absolute terms, the average effect of intensive follow‐up on colorectal cancer‐specific survival was 15 fewer colorectal cancer‐specific survival deaths per 1000 patients, but the true effect could lie between 47 fewer to 12 more per 1000 patients. </p> <p>Relapse‐free survival: we found intensive follow‐up made little or no difference (HR 1.05, 95% CI 0.92 to 1.21; I² = 41%; high‐quality evidence). There were 2254 relapses among 8047 participants enrolled in 16 studies. The average effect of intensive follow‐up on relapse‐free survival was 17 more relapses per 1000 patients, but the true effect could lie between 30 fewer and 66 more per 1000 patients. </p> <p>Salvage surgery with curative intent: this was more frequent with intensive follow‐up (risk ratio (RR) 1.98, 95% CI 1.53 to 2.56; I² = 31%; high‐quality evidence). There were 457 episodes of salvage surgery in 5157 participants enrolled in 13 studies. In absolute terms, the effect of intensive follow‐up on salvage surgery was 60 more episodes of salvage surgery per 1000 patients, but the true effect could lie between 33 to 96 more episodes per 1000 patients. </p> <p>Interval (symptomatic) recurrences: these were less frequent with intensive follow‐up (RR 0.59, 95% CI 0.41 to 0.86; I² = 66%; moderate‐quality evidence). There were 376 interval recurrences reported in 3933 participants enrolled in seven studies. Intensive follow‐up was associated with fewer interval recurrences (52 fewer per 1000 patients); the true effect is between 18 and 75 fewer per 1000 patients. </p> <p>Intensive follow‐up probably makes little or no difference to quality of life, anxiety, or depression (reported in 7 studies; moderate‐quality evidence). The data were not available in a form that allowed analysis. </p> <p>Intensive follow‐up may increase the complications (perforation or haemorrhage) from colonoscopies (OR 7.30, 95% CI 0.75 to 70.69; 1 study, 326 participants; very low‐quality evidence). Two studies reported seven colonoscopic complications in 2292 colonoscopies, three perforations and four gastrointestinal haemorrhages requiring transfusion. We could not combine the data, as they were not reported by study arm in one study. </p> <p>The limited data on costs suggests that the cost of more intensive follow‐up may be increased in comparison with less intense follow‐up (low‐quality evidence). The data were not available in a form that allowed analysis. </p> </section> <section id="CD002200-sec-0007"> <h3 class="title" id="CD002200-sec-0007">Authors' conclusions</h3> <p>The results of our review suggest that there is no overall survival benefit for intensifying the follow‐up of patients after curative surgery for colorectal cancer. Although more participants were treated with salvage surgery with curative intent in the intensive follow‐up groups, this was not associated with improved survival. Harms related to intensive follow‐up and salvage therapy were not well reported. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002200-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002200-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002200-abs-0014">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002200-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002200-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002200-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002200-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002200-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002200-abs-0016">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002200-abs-0015">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002200-abs-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002200-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002200-abs-0005" lang="en"> <h3>Follow‐up strategies for participants treated for non‐metastatic colorectal cancer</h3> <p><b>What is the issue?</b> </p> <p>Colorectal cancer affects about 1 in 20 people in high‐income countries. Most patients (about two thirds) have curable disease. Follow‐up after surgical resection +/‐ chemotherapy treatment usually means visits to the doctor as well as having some tests. Many people believe that follow‐up saves lives, but we are not sure how often the patient should see the doctor and what tests they should have, and when. </p> <p><b>Why is it important?</b> </p> <p>Follow‐up is expensive, it can make patients anxious around the time of their visit, and can be inconvenient. Tests are expensive and can have side effects. If tests find that cancer has come back in a person who feels well, but treatment cannot cure them, finding the recurrent cancer may not have helped that person or their family. </p> <p><b>We asked...</b> </p> <p>We asked if follow‐up (i.e. tests and doctor visits) after colorectal cancer has been treated curatively is helpful. We looked at all different kinds of follow‐up: some versus none; more tests versus fewer tests; and follow‐up done by surgeons, general practitioners (GPs), or nurses. </p> <p><b>We found...</b> </p> <p>We found 19 studies, including 13,216 participants. Our results are presented along with a judgement of quality which reflects how certain we are about the results. We found that follow‐up did not improve overall survival (high‐quality evidence), colorectal cancer‐specific survival (moderate‐quality evidence), or relapse‐free survival (high‐quality evidence). If patients have follow‐up, they are much more likely to have surgery if the cancer is detected again (high‐quality evidence). With follow‐up, more asymptomatic 'silent' cancer relapses are likely to be found at planned visits (moderate‐quality evidence). Harmful side effects (harms) from tests were not common, but more intensive follow‐up may increase harms (reported in two studies; very low‐quality evidence). Costs may be increased with more intensive follow‐up (low‐quality evidence). More intensive follow‐up probably makes little or no difference for quality of life (moderate‐quality evidence). </p> <p><b>This means...</b> </p> <p>The information we have now suggests that there is little benefit from intensifying follow‐up, but there is also little evidence about quality of life, harms, and costs. We do not know what is the best way to follow patients treated for non‐metastatic (no secondaries) colorectal cancer, or if we should at all. We know little about the costs of follow‐up in this setting. Consumer needs and concerns with respect to the value of follow‐up require further research. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002200-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002200-sec-0116">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002200-sec-0189">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002200-sec-0116"></div> <h3 class="title" id="CD002200-sec-0117">Implications for practice</h3> <section id="CD002200-sec-0117"> <p>The results of this review suggest that intensifying clinical follow‐up for participants with colorectal cancer after curative treatment does not improve survival outcomes. The exact details of the optimal follow‐up regimen still need clarification, but limiting follow‐up intensity does not seem to be disadvantageous. </p> </section> <h3 class="title" id="CD002200-sec-0118">Implications for research</h3> <section id="CD002200-sec-0118"> <p>Clinicians are encouraged to enrol their participants in any ongoing studies in this field. Such studies may reflect advances in imaging and surgical technique and the use of adjuvant therapies. All investigators are encouraged to explicitly document any harms relating to follow‐up and subsequent interventions. </p> <p>Separate research programmes should explore patient needs and concerns relating to the value of follow‐up, incorporating other study designs, using qualitative as well as quantitative methods. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002200-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002200-sec-0029"></div> <div class="table" id="CD002200-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intensive follow‐up compared to less intensive follow‐up for patients treated for colorectal cancer with curative intent</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intensive follow‐up compared to less intensive follow‐up for patients treated for colorectal cancer with curative intent</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> people with non‐metastatic colorectal cancer treated with curative intent </p> <p><b>Setting:</b> primary and secondary care </p> <p><b>Interventions:</b> more intensive follow‐up (clinic visits and investigations aimed at detecting recurrence) </p> <p><b>Comparison:</b> less intensive follow‐up </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with less intensive follow‐up</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with intensive follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 8 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12,528<br/> (15 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.80 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 fewer per 1000<br/> (60 fewer to 9 more)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Colorectal cancer‐specific survival</b><br/> Follow‐up: range 8 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>11,771<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/> (0.81 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/> (47 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relapse‐free survival</b><br/> Follow‐up: range 48 months to 120 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>8047<br/> (16 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/> (0.92 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 more per 1000<br/> (30 fewer to 66 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Salvage surgery</b> (surgery at relapse with curative intent)<br/> Follow‐up: range 2 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5157<br/> (13 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.98<br/> (1.53 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 more per 1000<br/> (33 more to 96 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interval recurrences</b> (recurrence CRC diagnosed between scheduled follow‐up visits)<br/> Follow‐up: range 2 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3933<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/> (0.41 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 fewer per 1000<br/> (75 fewer to 18 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Harms</b> </p> <p>Colonoscopy complications ‐ bowel perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>326</p> <p>(1 RCT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very Low<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.83</p> <p>(0.36 to 131.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>CRC:</b> colorectal cancer; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> Peto odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for imprecision because there were more than 300 events.<br/> <sup>b</sup>Confidence intervals include 1 and exclude clinically meaningful benefit or harm.<br/> <sup>c</sup>We used the number of events in the control arms of the included studies to derive absolute values.<br/> <sup>d</sup>Downgraded because we deemed 192/468 (41%) events from studies at high risk of bias because of incomplete follow‐up.<br/> <sup>e</sup>Not downgraded because prespecified sensitivity analysis explained heterogeneity on basis of study age.<br/> <sup>f</sup>Downgraded because we deemed 95/178 (58%) events from studies at high risk of bias because of incomplete follow‐up.<br/> <sup>g</sup>Downgraded for risk of bias related to lack of blinding and imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002200-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002200-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002200-sec-0140">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD002200-sec-0030"></div> <section id="CD002200-sec-0031"> <h3 class="title" id="CD002200-sec-0031">Description of the condition</h3> <p>Colorectal cancer is a commonly diagnosed malignancy affecting about one person in 20 in most westernised countries (<a href="./references#CD002200-bbs2-0052" title="Statistical Research and Applications Branch National Cancer Institute. DevCan: probability of developing or dying of cancer software. Version 6.7.0. Statistical Research and Applications Branch National Cancer Institute, 2005. ">DevCan 2005</a>). Approximately two‐thirds of patients will present with potentially curable disease (by surgery plus or minus adjuvant therapies). Of these, 50% to 60% will relapse with metastatic disease (<a href="./references#CD002200-bbs2-0070" title="LeeWS , YunSH , ChunHK , LeeWY , YunHR , KimJ , et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. International Journal of Colorectal Diseases2007;22(6):699‐704. ">Lee 2007</a>; <a href="./references#CD002200-bbs2-0095" title="VanCutsemEM , NordlingerB , AdamR , KöhneCH , PozzoC , PostonG , et al. European Colorectal Metastases Treatment Group. Towards a pan‐European consensus on the treatment of patients with colorectal liver metastases. European Journal of Cancer2006;42(14):2212‐21. ">Van Cutsem 2006</a>; <a href="./references#CD002200-bbs2-0102" title="YooPS , Lopez‐SolerRI , LongoWE , ChaCH . Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clinical Colorectal Cancer2006;6(3):202‐7. ">Yoo 2006</a>). Surgeons, oncologists, and other health professionals caring for people with colorectal cancer have pursued a number of strategies to try to improve clinical outcomes. These have included population screening, better diagnostic testing, improved surgical and anaesthetic techniques, and more widespread utilisation of effective adjuvant therapies. </p> <p>After definitive treatment is completed, clinician attention turns to follow‐up strategies designed to detect recurrence at a stage when further curative procedures can be used. Follow‐up strategies have also been developed in order to detect new curable metachronous (i.e. occurring at different times) primary tumours. There is overlap between these two strategies; this current review focuses on the former issue of strategies designed to detect curable recurrences of the original cancer. These include recurrences that are localised in either the lung, liver, abdomen, or pelvis and can be completely resected or ablated with curative intent. </p> <p>Following patients after definitive treatment for cancer has become a traditional component of medical care (<a href="./references#CD002200-bbs2-0055" title="EdelmanMJ , MeyersFJ , SiegelD . The utility of follow‐up testing after curative cancer therapy: a critical review and economic analysis. Journal of General Internal Medicine1997;12(5):318‐31. ">Edelman 1997</a>). It is likely that clinicians follow patients after curative treatment for colorectal cancer at least in part to provide positive feedback on their management but also to assess the toxicities of treatment and to provide more accurate outcome data (<a href="./references#CD002200-bbs2-0039" title="AudisioRA , Setti‐CarraroP , SegalaM , CapkoD , AndreoniB , TiberioG . Follow‐up in colorectal cancer patients: a cost‐benefit analysis. Annals of Surgical Oncology1996;3(4):349‐57. ">Audisio 1996</a>). Patients and their clinicians develop relationships during treatment and follow‐up that can make it hard to discharge patients and return responsibility for care back to their primary physician in the community (<a href="./references#CD002200-bbs2-0040" title="AudisioRA , RobertsonC . Colorectal cancer follow‐up: perspectives for future studies. European Journal of Surgical Oncology2000;26(4):329‐37. ">Audisio 2000</a>). As a result, a practising clinician can accumulate a large number of follow‐up patients, and the surveillance of this cohort consumes significant resources. </p> <p>The opportunity cost of the resources involved is considerable, limiting the care that the clinician can provide for other individuals. Few clinicians restrict colorectal cancer follow‐up visits to clinical examination only, and the temptation to order routine investigations is often reinforced by patients who desire tests to 'prove' that their disease is under control (<a href="./references#CD002200-bbs2-0040" title="AudisioRA , RobertsonC . Colorectal cancer follow‐up: perspectives for future studies. European Journal of Surgical Oncology2000;26(4):329‐37. ">Audisio 2000</a>; <a href="./references#CD002200-bbs2-0069" title="KievitJ . Colorectal cancer follow‐up: a reassessment of empirical evidence on effectiveness. European Journal of Surgical Oncology2000;26(4):322‐8. ">Kievit 2000</a>). Clinicians justify this approach by claiming that recurrences are being detected earlier than would otherwise occur and that patient outcomes are improved as a result (<a href="./references#CD002200-bbs2-0069" title="KievitJ . Colorectal cancer follow‐up: a reassessment of empirical evidence on effectiveness. European Journal of Surgical Oncology2000;26(4):322‐8. ">Kievit 2000</a>). </p> </section> <section id="CD002200-sec-0032"> <h3 class="title" id="CD002200-sec-0032">Description of the intervention</h3> <p>Follow‐up programmes in colorectal cancer should be based on the anatomic and temporal patterns of recurrence (<a href="./references#CD002200-bbs2-0040" title="AudisioRA , RobertsonC . Colorectal cancer follow‐up: perspectives for future studies. European Journal of Surgical Oncology2000;26(4):329‐37. ">Audisio 2000</a>; <a href="./references#CD002200-bbs2-0055" title="EdelmanMJ , MeyersFJ , SiegelD . The utility of follow‐up testing after curative cancer therapy: a critical review and economic analysis. Journal of General Internal Medicine1997;12(5):318‐31. ">Edelman 1997</a>). The most important phase of follow‐up is the first two to three years after primary resection, as during this time, the majority of recurrences will become apparent (<a href="./references#CD002200-bbs2-0044" title="BöhmB , SchwenkW , HuckeHP , StockW . Does methodic long‐term follow‐up affect survival after curative resection of colorectal carcinoma?. Diseases of the Colon and Rectum1993;36(3):280‐6. ">Böhm 1993</a>; <a href="./references#CD002200-bbs2-0077" title="OvaskaJT , JärvinenHJ , MecklinJP . The value of a follow‐up programme after radical surgery for colorectal carcinoma. Scandinavian Journal of Gastroenterology1989;24(4):416‐22. ">Ovaska 1989</a>). The liver is the most common site of metastases from colorectal cancer. A small proportion of these patients (10% to 20%) will have liver metastases that are distributed within the liver in such a fashion that makes them amenable to surgical resection or ablation (<a href="./references#CD002200-bbs2-0034" title="AlbertsSR , HorvathWL , SternfeldWC , GoldbergRM , MahoneyMR , DakhilSR , et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver‐only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. Journal of Clinical Oncology2005;23(36):9243‐9. ">Alberts 2005</a>; <a href="./references#CD002200-bbs2-0075" title="MuratoreA , ZorziD , BouzariH , AmisanoM , MassuccoP , SpertiE , et al. Asymptomatic colorectal cancer with un‐resectable liver metastases: immediate colorectal resection or up‐front systemic chemotherapy?. Annals of Surgical Oncology2007;14(2):766‐70. ">Muratore 2007</a>). Published series of patients undergoing such surgical interventions (with significant numbers of long‐term survivors) encourage this approach (<a href="./references#CD002200-bbs2-0046" title="ChotiMA , SitzmannJV , TiburiMF , SumetchotimethaW , RangsinR , SchulickRD , et al. Trends in long‐term survival following liver resection for hepatic colorectal metastases. Annals of Surgery2002;235(6):759‐66. ">Choti 2002</a>; <a href="./references#CD002200-bbs2-0068" title="KanasGP , TaylorA , PrimroseJN , LangebergWJ , KelshMA , MowatFS , et al. Survival after liver resection in metastatic colorectal cancer: review and meta‐analysis of prognostic factors. Clinical Epidemiology2012;4:283‐301. ">Kanas 2012</a>; <a href="./references#CD002200-bbs2-0078" title="PawlikTM , ScogginsCR , ZorziD , AbdallaEK , AndresA , EngC , et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Annals of Surgery2005;241(5):715‐22. ">Pawlik 2005</a>). A number of strategies have been proposed to detect liver metastases at an early stage in order to identify such patients; these include the monitoring of blood tests (liver function, level of serum carcinoembryonic antigen (CEA)), and routine imaging of the liver and lung (<a href="./references#CD002200-bbs2-0057" title="FleischerDE , GoldbergSB , BrowningTH , CooperJN , FriedmanE , GoldnerFH , et al. Detection and surveillance of colorectal cancer. JAMA1989;261(4):580‐5. ">Fleischer 1989</a>; <a href="./references#CD002200-bbs2-0092" title="SugarbakerPH , GianolaFJ , DwyerA , NeumanNR . A simplified plan for follow‐up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery1987;102(1):79‐87. ">Sugarbaker 1987</a>). </p> <p>The psychological outcomes of follow‐up programmes for people with cancer can be positive or negative. Positive outcomes include reassurance and support. The negative outcomes include false reassurance, increased anxiety, fear and disappointment associated with early detection of an incurable recurrence, morbidity and mortality associated with procedures performed as a result of abnormal results, and distress caused by false‐positive results. Appropriate quality‐of‐life measurements could provide information about these outcomes. </p> <p>Follow‐up can comprise clinic visits, examinations, and tests (blood tests and endoscopic and radiological examinations). More intensive follow‐up may consist of an increased frequency of clinic visits, tests, and examinations in comparison with none or fewer clinic visits, tests, and examinations. </p> </section> <section id="CD002200-sec-0033"> <h3 class="title" id="CD002200-sec-0033">How the intervention might work</h3> <p>Follow‐up programmes in colorectal cancer are thought to increase the early detection of recurrence at a stage when further curative procedures can be used, as well as new curable metachronous primary tumours, thereby, improving survival outcomes (<a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>). </p> </section> <section id="CD002200-sec-0034"> <h3 class="title" id="CD002200-sec-0034">Why it is important to do this review</h3> <p>Whether systematic follow‐up can alter long‐term clinical outcomes for colorectal cancer remains controversial (<a href="./references#CD002200-bbs2-0079" title="PfisterDG , BensonAB , SomerfieldMR . Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. New England Journal of Medicine2004;350(23):2375‐82. ">Pfister 2004</a>). Whilst some commentators have concluded that follow‐up is worthwhile (<a href="./references#CD002200-bbs2-0060" title="GerdesH . Surveillance after colon cancer: is it worthwhile?. Gastroenterology1990;99(6):1849‐51. ">Gerdes 1990</a>), others have questioned its effectiveness (<a href="./references#CD002200-bbs2-0069" title="KievitJ . Colorectal cancer follow‐up: a reassessment of empirical evidence on effectiveness. European Journal of Surgical Oncology2000;26(4):322‐8. ">Kievit 2000</a>; <a href="./references#CD002200-bbs2-0071" title="McArdleC . ABC of colorectal cancer: effectiveness of follow‐up. BMJ2000;321(7272):1332‐5. ">McArdle 2000</a>). The variation in follow‐up programmes, in terms of timing and frequency of clinician visits and the investigations undertaken by clinicians, is considerable (<a href="./references#CD002200-bbs2-0047" title="CollopyBT . The follow‐up of patients after resection for large bowel cancer, May 1992. Colorectal Surgical Society of Australia. Medical Journal of Australia1992;157(9):633‐4. ">Collopy 1992</a>; <a href="./references#CD002200-bbs2-0048" title="ConnorS , FrizelleFA , BagshawPF . Follow‐up after attempted curative surgery for colorectal cancer; postal survey of New Zealand surgeons' practice. New Zealand Medical Journal2001;114(1129):151‐3. ">Connor 2001</a>; <a href="./references#CD002200-bbs2-0096" title="VernavaAM , LongoWE , VirgoKS , CoplinMA , WadeTP , JohnsonFE . Current follow‐up strategies after resection of colon cancer. Results of a survey of members of the American Society of Colon and Rectal Surgeons. Diseases of the Colon and Rectum1994;37(6):573‐83. ">Vernava 1994</a>; <a href="./references#CD002200-bbs2-0097" title="VirgoKS , VernavaAM , LongoWE , McKirganLW , JohnsonFE . Cost of patient follow‐up after potentially curative colorectal cancer treatment. JAMA1995;273(23):1837‐41. ">Virgo 1995</a>). Routine follow‐up has the potential to create psychological harm in patients, and any such disadvantages need to be outweighed by improved clinical outcomes (such as overall survival) that matter to patients. Data from follow‐up studies in other cancers (e.g. breast cancer and overall survival) is not encouraging in this regard (<a href="./references#CD002200-bbs2-0085" title="RojasMP , TelaroE , RussoA , FossatiR , PalliD , Rosselli Del TurcoM , et al. Follow‐up strategies for women treated for early breast cancer. Cochrane Database of Systematic Reviews2005, Issue 1. [DOI: 10.1002/14651858.CD001768.pub2] ">Rojas 2005</a>). </p> <p>Therefore, we conducted a systematic review of randomised controlled trials exploring questions relating to the effectiveness of follow‐up strategies in colorectal cancer patients treated with curative intent. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002200-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002200-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002200-sec-0145">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002200-sec-0035"></div> <p>To assess the effect of follow‐up programmes (follow‐up versus no follow‐up, follow‐up strategies of varying intensity, and follow‐up in different healthcare settings) on overall survival for patients with colorectal cancer treated with curative intent. Secondary objectives are to assess relapse‐free survival, salvage surgery, interval recurrences, quality of life, and the harms and costs of surveillance and investigations. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002200-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002200-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002200-sec-0146">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002200-sec-0036"></div> <section id="CD002200-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002200-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) comparing different follow‐up strategies for participants with colorectal cancer. These included comparisons of follow‐up versus no follow‐up, follow‐up strategies of varying intensity (differing frequency or quantity of testing, or both), and follow‐up in different healthcare settings (e.g. primary care versus hospital). Cluster‐RCTs were eligible. </p> </section> <section id="CD002200-sec-0039"> <h4 class="title">Types of participants</h4> <p>Male and female patients of any age with histologically proven adenocarcinoma of the colon or rectum, staged as T1‐4N0‐2M0 (<a href="./references#CD002200-bbs2-0056" title="EdgeSB , ByrdSR , ComptonCC . In: EdgeSB , ByrdSR , ComptonCC , et al. editor(s). AJCC Cancer Staging Manual. 7th Edition. New York: Springer Verlag, 2010. ">Edge 2010</a>), treated surgically with curative intent (plus or minus adjuvant treatment). </p> </section> <section id="CD002200-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Follow‐up visits with any health professionals in any setting, including symptom enquiry, clinical examination, and procedures and investigations (including but not limited to colonoscopy, blood tests, faecal analysis, and radiological examinations). </p> </section> <section id="CD002200-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD002200-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002200-list-0001"> <li> <p>Overall survival (measured from the time of randomisation in the study)</p> </li> </ol> </p> </section> <section id="CD002200-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002200-list-0002"> <li> <p>Colorectal cancer‐specific survival (measured from the time of randomisation in the study) </p> </li> <li> <p>Relapse‐free survival (measured from the time of randomisation in the study)</p> </li> <li> <p>Salvage surgery (surgery performed with curative intent for relapse of colorectal cancer) </p> </li> <li> <p>Interval recurrences (relapse of colorectal cancer detected between follow‐up visits)</p> </li> <li> <p>Quality of life (using study‐specific instruments, including but not limited to FACT (Functional Assessment of Cancer Therapy), EORTC QLQ‐C30 (European Organization for Research and Treatment of Cancer Quality of Life), and EORTC‐CRC (<a href="./references#CD002200-bbs2-0045" title="CellaDF , TulskyDS , GrayG , SarafianB , LinnE , BonomiA , et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology1993;11(3):570‐9. ">Cella 1993</a>; <a href="./references#CD002200-bbs2-0090" title="SprangersMA , CullA , BjordalK , GroenvoldM , AaronsonNK . The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Quality of Life Research1993;2(4):287‐95. ">Sprangers 1993</a>; <a href="./references#CD002200-bbs2-0101" title="WhistanceRN , ConroyT , ChieW , CostantiniA , SezerO , KollerM , et al. European Organisation for the Research and Treatment of Cancer Quality of Life Group. Clinical and psychometric validation of the EORTC QLQ‐CR29 questionnaire module to assess health‐related quality of life in patients with colorectal cancer. European Journal of Cancer2009;45(17):3017‐26. [DOI: 10.1016/j.ejca.2009.08.014.] ">Whistance 2009</a>) </p> </li> <li> <p>Harms, including but not limited to psychological harms, investigation‐related complications, and waste of resources </p> </li> <li> <p>Costs of surveillance (including investigations)</p> </li> </ol> </p> </section> </section> </section> <section id="CD002200-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002200-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases with no language restriction:</p> <p> <ol id="CD002200-list-0003"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 4) in the Cochrane Library using the strategy in <a href="./appendices#CD002200-sec-0122">Appendix 1</a>; </p> </li> <li> <p>MEDLINE Ovid (from 1950 to 5 April 2019) using the strategy in <a href="./appendices#CD002200-sec-0123">Appendix 2</a>; </p> </li> <li> <p>Embase Ovid (from 1974 to 5 April 2019) using the strategy in <a href="./appendices#CD002200-sec-0124">Appendix 3</a>; </p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; from 1981 to April 2019) using the strategy in <a href="./appendices#CD002200-sec-0125">Appendix 4</a>; and </p> </li> <li> <p>Science Citation Index (from 1900 to April 2019) using the strategy in <a href="./appendices#CD002200-sec-0126">Appendix 5</a>. </p> </li> </ol> </p> <p>For the Review first published in the Cochrane Library 2002 issue 1, we also searched the electronic database CANCERLIT, which stopped existing in 2003. </p> </section> <section id="CD002200-sec-0046"> <h4 class="title">Searching other resources</h4> <section id="CD002200-sec-0047"> <h5 class="title">Trials registries</h5> <p>We searched the following trials registries:</p> <p> <ol id="CD002200-list-0004"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov; <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; (searched April 2019); and </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform; <a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; (searched April 2019). </p> </li> </ol> </p> </section> <section id="CD002200-sec-0048"> <h5 class="title">Handsearching</h5> <p>We searched the following journals and conference proceedings:</p> <p> <ol id="CD002200-list-0005"> <li> <p>American Society for Clinical Oncology (ASCO) (1995 to 2010, 2012‐2018);</p> </li> <li> <p>European Society for Therapeutic and Radiation Oncology (1990, 1993, 2000 to 2010, 2012 to 2018); and </p> </li> <li> <p>International Journal of Radiation Oncology Biology Physics: proceedings of the American Society for Radiation Oncology (ASTRO) (2011 to 2018). </p> </li> </ol> </p> <p>We searched reference lists of published articles and previous systematic reviews and made personal contact with experts. We identified non‐English and unpublished studies. </p> </section> <section id="CD002200-sec-0049"> <h5 class="title">Grey literature</h5> <p>We searched OpenGrey (<a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu;</a> 8 April 2019). </p> </section> </section> </section> <section id="CD002200-sec-0050"> <h3 class="title" id="CD002200-sec-0050">Data collection and analysis</h3> <section id="CD002200-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BEH and GMJ) checked the titles and abstracts identified from the databases. The review authors obtained the full text of all studies of possible relevance for independent assessment, decided which studies met the inclusion criteria, and graded their methodological quality. Discussion between the review authors resolved any disagreement. We contacted authors of primary studies for clarification where necessary: we contacted the authors for <a href="./references#CD002200-bbs2-0024" title="BarillariP , RamacciatoG , ManettiG , BovinoA , SammartinoP , StipaV . Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Diseases of the Colon and Rectum1996;39(4):388‐93. ">Barillari 1996</a> on 10 November 2018 but have had no response. We did not use the reported outcomes as criteria for including studies. We included studies irrespective of their publication status. We documented the selection process using <a href="./references#CD002200-bbs2-0049" title="Veritas Health Innovation. Covidence. Version accessed 23 October 2015. Melbourne, Australia: Veritas Health Innovation. ">Covidence</a> and presented the details of the search in a PRISMA diagram (<a href="./references#CD002200-bbs2-0073" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). Reasons for exclusion are presented in the '<a href="./references#CD002200-sec-0137" title="">Characteristics of excluded studies</a>' table. We collated multiple reports of the same study so that each study, rather than the report, was the unit of interest in the review, and we identified the primary source. </p> </section> <section id="CD002200-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (BEH and GMJ) independently performed data extraction; we contacted the authors of studies to provide missing data where possible. We entered data into a previously piloted data form then into <a href="./references#CD002200-bbs2-0049" title="Veritas Health Innovation. Covidence. Version accessed 23 October 2015. Melbourne, Australia: Veritas Health Innovation. ">Covidence</a>. One review author (BEH) entered data into Review Manager 5 (RevMan 5), which a second author (AS) checked (<a href="./references#CD002200-bbs2-0084" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We resolved any disagreements by discussion. We extracted the following data when available: </p> <p> <ol id="CD002200-list-0006"> <li> <p>number of participants;</p> </li> <li> <p>the age and status of the participants;</p> </li> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>setting;</p> </li> <li> <p>treatment regimen;</p> </li> <li> <p>follow‐up details; and</p> </li> <li> <p>survival, adverse events, and quality‐of‐life indices.</p> </li> </ol> </p> <p>We collected data that were sufficient to populate a table of characteristics of included studies. For studies where only a subset of the participants recruited were eligible for inclusion, we included them if they reported data for that subgroup separately. Where a study had more than one study arm, such as <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>, we combined those intervention study arms that met the inclusion criteria and compared them with the control arm; this ensured we did not double‐count data. When we performed subgroup analysis for <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>, we combined the two arms with measured carcinoembryonic antigen (CEA) and the two arms that used computerised tomography (CT). We compared the magnitude and direction of effects reported by studies with how they were presented in the review. </p> <p>In order to report time‐to‐event data, we used the RevMan 5 calculator (<a href="./references#CD002200-bbs2-0084" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and a spreadsheet developed by Matthew Sydes (<a href="./references#CD002200-bbs2-0093" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007; Vol. 8:16. ">Tierney 2007</a>), to derive observed (O) and log‐rank expected events (E) (O‐E) and variance. <a href="./references#CD002200-bbs2-0093" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007; Vol. 8:16. ">Tierney 2007</a> presents 11 methods for calculating a hazard ratio (HR) or associated statistics, or both, from published time‐to‐event‐analyses into a practical, less statistical guide. The methods we used to do so were dependent on the available information in the texts, and we report them as follows. </p> <p>Reports presenting HRs and 95% confidence intervals allowed application of method 3 in <a href="./references#CD002200-bbs2-0093" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007; Vol. 8:16. ">Tierney 2007</a> and were available for analysis as follows: </p> <p> <ol id="CD002200-list-0007"> <li> <p>overall survival (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> (please note that for <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>, we used the RevMan 5 calculator to derive the HR, because this agreed with the P value given in the text)); </p> </li> <li> <p>colorectal cancer‐specific survival (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>); and </p> </li> <li> <p>relapse‐free survival (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>). </p> </li> </ol> </p> <p>In reports with a P value, events in each arm, and where the randomisation ratio was 1:1, we used method 7 in <a href="./references#CD002200-bbs2-0093" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007; Vol. 8:16. ">Tierney 2007</a> to derive O‐E and variance. Such studies contributed to the following analyses: </p> <p> <ol id="CD002200-list-0008"> <li> <p>overall survival (<a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> (for <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>, we used the RevMan 5 calculator to derive the HR, because the statistic presented in the text was adjusted for confounding; this was also the approach that the systematic review <a href="./references#CD002200-bbs2-0080" title="Pita‐FernándezS , Alhayek‐AíM , González‐MartinC , López‐CalviñoB , Seoane‐PilladoT , Pértega‐DíazS . Intensive follow‐up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta‐analysis. Annals of Oncology Advance Access2014;00:1‐12. ">Pita‐Fernández 2014</a> used for this study)); </p> </li> <li> <p>colorectal cancer‐specific survival (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>); and </p> </li> <li> <p>relapse‐free survival (<a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>). </p> </li> </ol> </p> <p>In reports where we extracted data from the survival curve, assuming constant censoring, we used method 10 in <a href="./references#CD002200-bbs2-0093" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007; Vol. 8:16. ">Tierney 2007</a> for two studies contributing to the outcome of overall survival (<a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>). </p> <p>For relapse‐free survival, we extracted curve data with numbers at risk (method 11) for <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>. </p> </section> <section id="CD002200-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two study authors (BEH and GMJ) constructed and presented 'Risk of bias' tables using the Cochrane 'Risk of bias' tool, resolving any disagreements by discussion (<a href="./references#CD002200-bbs2-0064" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8:Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We evaluated the following domains: </p> <p> <ol id="CD002200-list-0009"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete follow‐up (exclusions, attrition);</p> </li> <li> <p>selective reporting; and</p> </li> <li> <p>other bias, including but not limited to early stopping, inadequate duration of follow‐up, or baseline imbalances. </p> </li> </ol> </p> <p>We graded domains as at low risk of bias, high risk of bias, or unclear risk of bias (using the criteria in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Table 8.5d) (see Appendix 6), with our reasons and supporting evidence detailed in the tables (<a href="./references#CD002200-bbs2-0064" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8:Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We summarised the risk of bias for each of the key study outcomes (overall survival, disease‐specific survival, relapse‐free survival, salvage surgery, interval recurrences, and complications of colonoscopy). </p> </section> <section id="CD002200-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <p>Where possible, we conducted time‐to‐event analyses for overall survival, colorectal cancer‐specific survival, and relapse‐free survival. We expressed the results as hazard ratios (HR) with 95% confidence intervals (CI) when the relevant information was available in the text or could be derived. Where necessary, we derived the HR using the RevMan 5 calculator (<a href="./references#CD002200-bbs2-0084" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and calculated associated statistics using an Excel spreadsheet developed by Matthew Sydes (Cancer Division of the Medical Research Council (MRC) Clinical Trials Unit) in collaboration with the Meta‐analysis Group of the MRC Clinical Trials Unit, London (<a href="./references#CD002200-bbs2-0093" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007; Vol. 8:16. ">Tierney 2007</a>). We reported risk ratios (RR) and 95% CIs for dichotomous outcomes and would use the mean difference and 95% CI to report continuous outcomes. In the case of rare events (Analysis 1.6) we used the Peto odds ratio (OR; <a href="./references#CD002200-bbs2-0051" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). We interpreted a statistically non‐significant result (P value larger than 0.05) as a finding of uncertainty unless the confidence intervals were sufficiently narrow to rule out a potentially important magnitude of effect. We defined confidence intervals between 0.75 and 1.25 as excluding clinically meaningful benefits or harms. </p> </section> <section id="CD002200-sec-0055"> <h4 class="title">Unit of analysis issues</h4> <p>All of the RCTs were parallel in design, with participants being the unit of randomisation; therefore, we had no unit of analysis issues. </p> </section> <section id="CD002200-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> to request the raw data. We were informed on 20 April 2015 that because of personnel changes, the authors were unable to retrieve the data, which meant we were not able to report overall survival data for this study. Because they plotted two curves for each study arm, it was not possible to extract data for use in time‐to‐event analysis. We were in contact with the study authors for <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> on 18 February 2016, who kindly provided us with unpublished data, which we were able to include for the outcomes 'Interval recurrences' and 'Salvage surgery' (<a href="./references#CD002200-bbs2-0058" title="FossatiR . Colorectal cancer follow‐up review update overdue [personal communication]. Email to: GM Jeffery 4 May 2015. ">Fossati 2015</a>). Therefore, all analyses were by intention‐to‐treat. </p> </section> <section id="CD002200-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity both visually and statistically using the Chi² test of heterogeneity (<a href="./references#CD002200-bbs2-0035" title="AltmanDG . Practical statistics for medical research. London: Chapman and Hall, 1992. ">Altman 1992</a>; <a href="./references#CD002200-bbs2-0098" title="WalkerAM , Martin‐MorenoJM , ArtalejoFR . Odd man out: a graphical approach to meta‐analysis. American Journal of Public Health1988;78(8):961‐6. ">Walker 1988</a>), and I² statistic (<a href="./references#CD002200-bbs2-0051" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>; <a href="./references#CD002200-bbs2-0063" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>). The criterion for identification of heterogeneity is a P value less than 0.10 for the Chi² test (acknowledging the limitations of this process) and an I² statistic value of greater than 50%. Where we identified significant heterogeneity, we first checked the data to ensure it was not due to error, explored the potential causes of it, and made a cautious attempt to explain the heterogeneity. </p> </section> <section id="CD002200-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed the potential impact of reporting biases by the use of a funnel plot for the four outcomes that included data from 10 or more studies (overall survival, cancer‐specific survival, relapse‐free survival, and salvage surgery). Including 15 studies allowed us to visually assess whether small‐study effects were present or not. </p> </section> <section id="CD002200-sec-0059"> <h4 class="title">Data synthesis</h4> <p>We calculated a weighted treatment effect (using a random‐effects model) across studies using the Cochrane statistical package in RevMan 5 (<a href="./references#CD002200-bbs2-0084" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Where O‐E and variance were available, we used a log‐rank approach and a fixed‐effect model to synthesise data. We summated data where we judged the participants, interventions, and outcomes to be sufficiently similar to ensure a clinically meaningful answer. </p> </section> <section id="CD002200-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We used subgroup analyses to investigate possible differences in participant outcomes according to study variables that we believed could be effect modifiers. These included the use of CEA, CT, and PET‐CT (positron emission tomography–computed tomography) in the intensive follow‐up strategy when compared with no use or less frequent use (twice at most) in the control arm, and setting for follow‐up (general practitioner (GP)‐ or nurse‐led follow‐up compared with hospital follow‐up and 'dose' of follow‐up, that is, studies that compared the use of more visits and tests with fewer visits and tests). These subgroup analyses may help identify which investigations are useful in follow‐up for colorectal cancer and allow us to give specific guidance to clinicians. We used a formal statistical test to compare subgroups. </p> </section> <section id="CD002200-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We performed prespecified sensitivity analyses to test the strength of our conclusions by excluding studies judged to be at high risk of bias for the particular outcome concerned (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), and by study age (excluding those studies that completed accrual by 1996) (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>). </p> <p>We performed post hoc sensitivity analysis in response to reviewer suggestion by excluding one study (<a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>), where the intensity of follow‐up in the intensive arm was comparable with the intensity of follow‐up in the control arm of other studies. </p> <section id="CD002200-sec-0062"> <h5 class="title">'Summary of findings' tables</h5> <p>We evaluated the quality of evidence using the GRADE approach for the following outcomes (<a href="./references#CD002200-bbs2-0088" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html. ">Schünemann 2013</a>): </p> <p> <ol id="CD002200-list-0010"> <li> <p>overall survival;</p> </li> <li> <p>colorectal cancer‐specific survival;</p> </li> <li> <p>relapse‐free survival;</p> </li> <li> <p>salvage surgery;</p> </li> <li> <p>interval recurrences; and</p> </li> <li> <p>harms associated with surveillance.</p> </li> </ol> </p> <p>We used <a href="./references#CD002200-bbs2-0061" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version (accessed 07th August 2019). Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a> to present the quality of evidence for the aforementioned outcomes in 'Summary of findings' tables. We could downgrade the quality of the evidence by one (serious concern) or two levels (very serious concern) for the following reasons: risk of bias, inconsistency (unexplained heterogeneity, inconsistency of results), indirectness (indirect population, intervention, control, outcomes), imprecision (wide confidence intervals, single study), and publication bias. We could also downgrade the quality by one level due to a large summary effect. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002200-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002200-sec-0063"></div> <section id="CD002200-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD002200-sec-0065"> <h4 class="title">Results of the search</h4> <p>For this update, we screened 7571 references, of which we assessed 33 references in full. We identified four new studies for inclusion (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>), and we identified 9 additional references for four previously included studies (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>). In this update, we moved nine references referring to three studies that were previously either ongoing or awaiting assessment to included studies. We identified four new ongoing studies (<a href="./references#CD002200-bbs2-0027" title="NCT03413254 . Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases (COLOPEC‐II). clinicaltrials.gov/ct2/show/NCT03413254?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;draw=2&amp;rank=11 (accessed 9 January 2019). ">COLOPEC</a>; <a href="./references#CD002200-bbs2-0028" title="JakobsenIH , JuulT , BernsteinI , ChristensenP , JensenFS , JohansenC , et al. Follow‐up after rectal cancer: developing and testing a novel patient‐led follow‐up program. Study protocol. Acta Oncologica2017;56(2):307. NCT03622437 . Individual follow‐up after rectal cancer ‐ focus on the needs of the patient (FURCA). clinicaltrials.gov/ct2/show/NCT03622437?id=NCT03622437&amp;rank=1 (accessed 09 January 2019). ">FURCA</a>; <a href="./references#CD002200-bbs2-0030" title='GoereD , GlehenO , QuenetF , DucreuxM , GuilloitJ , TexierM , et al. Results of a randomized phase 3 study evaluating the potential benefit of a secondlook surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP‐ NTC01226394). Journal of Clinical Oncology2018;36(15S):3531. NCT01226394 . Multicentric phase III trial comparing simple follow‐up to exploratory laparotomy plus "in principle" HIPEC (hyperthermic intraperitoneal chemotherapy) in colorectal patients initially treated with surgery and adjuvant chemotherapy who have a high risk of developing colorectal peritoneal carcinomatosis. clinicaltrials.gov/ct2/show/NCT01226394?id=NCT01226394&amp;rank=1 (accessed 6 June 2018). '>ProphyloCHIP</a>; <a href="./references#CD002200-bbs2-0031" title="ACTRN126170000004369p . Shared care of colorectal cancer survivors ‐ a randomised controlled trial of hospital‐based follow up versus shared hospital / community follow up for survivors of colorectal cancer. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371925 (accessed 01 August 2018). JeffordM , EmeryJ , GrunfeldE , MartinA , RodgerP , MurrayAM , et al. SCORE: shared care of colorectal cancer survivors: protocol for a randomised controlled trial. Trials2017;18(1):506. ">SCORE</a>). </p> <p>In summary, this updated version of the review now includes a total of 82 references:</p> <p> <ol id="CD002200-list-0011"> <li> <p>63 references refer to 19 included studies (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>); </p> </li> <li> <p>five references refer to four excluded studies (<a href="./references#CD002200-bbs2-0020" title="KronborgO , HageE , DeichgraeberE . A prospective, partly randomized study of the effectiveness of repeated examination of the colon after polypectomy and radical surgery for cancer. Scandinavian Journal of Gasteroenterology1981;16(7):879‐84. ">Kronborg 1981</a>; <a href="./references#CD002200-bbs2-0021" title="NCT00182234 . SONICS ‐ Effectiveness of Specialist Oncology Nursing. clinicaltrials.gov/ct2/show/study/NCT00182234?term=NCT00182234&amp;rank=1 (accessed 23 July 2018). SussmanJ , BainbridgeD , WhelanTJ , BrazilK , ParpiaS , WiernikowskiJ , et al. Evaluation of a specialized oncology nursing supportive care intervention in newly diagnosed breast and colorectal cancer patients following surgery: a cluster randomized trial. Supportive Care in Cancer2018;26(5):1533‐41. ">NCT00182234</a>; <a href="./references#CD002200-bbs2-0022" title="SanoY , FujiiT , OdaY , MatsudaT , KozuT , KudoS , et al. A multicenter randomized controlled trial designed to evaluate follow‐up surveillance strategies for colorectal cancer: the Japan Polyp Study. Digestive Endoscopy2004;16(4):376‐8. ">Sano 2004</a>; <a href="./references#CD002200-bbs2-0023" title="SerranoP , GuC , HusienM , JalinkD , MartelG , TsangME , et al. Effect of PET‐CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: the long‐term results of a randomized controlled trial. Annals of Surgical Oncology. 2018; Vol. 25:1S. ">Serrano 2018</a>); </p> </li> <li> <p>three references refer to three studies awaiting assessment (<a href="./references#CD002200-bbs2-0024" title="BarillariP , RamacciatoG , ManettiG , BovinoA , SammartinoP , StipaV . Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Diseases of the Colon and Rectum1996;39(4):388‐93. ">Barillari 1996</a>; <a href="./references#CD002200-bbs2-0025" title="NCT00199654 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">NCT00199654</a>; <a href="./references#CD002200-bbs2-0026" title="UMN000001318 . Randomized control trial of follow‐up schedule after curative resection for colorectal cancer. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000001417 (accessed 6 April 2019). ">UMN000001318</a>); and </p> </li> <li> <p>11 references refer to six ongoing studies (<a href="./references#CD002200-bbs2-0027" title="NCT03413254 . Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases (COLOPEC‐II). clinicaltrials.gov/ct2/show/NCT03413254?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;draw=2&amp;rank=11 (accessed 9 January 2019). ">COLOPEC</a>; <a href="./references#CD002200-bbs2-0028" title="JakobsenIH , JuulT , BernsteinI , ChristensenP , JensenFS , JohansenC , et al. Follow‐up after rectal cancer: developing and testing a novel patient‐led follow‐up program. Study protocol. Acta Oncologica2017;56(2):307. NCT03622437 . Individual follow‐up after rectal cancer ‐ focus on the needs of the patient (FURCA). clinicaltrials.gov/ct2/show/NCT03622437?id=NCT03622437&amp;rank=1 (accessed 09 January 2019). ">FURCA</a>; <a href="./references#CD002200-bbs2-0029" title="NCT01628211 . Second look laparoscopy in colorectal cancer (HIPEC) [Randomized phase 2 study comparing second look laparoscopy to standard follow up in patients with no radiologic evidence of disease at 6 months after complete resection of colorectal mucinous carcinoma]. clinicaltrials.gov/ct2/show/NCT01628211?term=NCT01628211&amp;rank=1 (first received 20 August 2014). ">HIPEC</a>; <a href="./references#CD002200-bbs2-0030" title='GoereD , GlehenO , QuenetF , DucreuxM , GuilloitJ , TexierM , et al. Results of a randomized phase 3 study evaluating the potential benefit of a secondlook surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP‐ NTC01226394). Journal of Clinical Oncology2018;36(15S):3531. NCT01226394 . Multicentric phase III trial comparing simple follow‐up to exploratory laparotomy plus "in principle" HIPEC (hyperthermic intraperitoneal chemotherapy) in colorectal patients initially treated with surgery and adjuvant chemotherapy who have a high risk of developing colorectal peritoneal carcinomatosis. clinicaltrials.gov/ct2/show/NCT01226394?id=NCT01226394&amp;rank=1 (accessed 6 June 2018). '>ProphyloCHIP</a>; <a href="./references#CD002200-bbs2-0031" title="ACTRN126170000004369p . Shared care of colorectal cancer survivors ‐ a randomised controlled trial of hospital‐based follow up versus shared hospital / community follow up for survivors of colorectal cancer. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371925 (accessed 01 August 2018). JeffordM , EmeryJ , GrunfeldE , MartinA , RodgerP , MurrayAM , et al. SCORE: shared care of colorectal cancer survivors: protocol for a randomised controlled trial. Trials2017;18(1):506. ">SCORE</a>; <a href="./references#CD002200-bbs2-0032" title="LepageC , PhelipJ‐M , CanyL , FarouxR , ManfrediS , AinJ‐F . Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Digestive and Liver Disease2015;47(7):529‐31. LepageC , PhelipJM , CanyL , MaillardE , LievreA , ChatellierT , et al. Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer‐PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology2016. NCT00995202 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">SURVEILLANCE</a>). </p> </li> </ol> </p> <p>There was considerable variation in the follow‐up strategies employed by the 19 studies; both the frequency of, the setting for, and the investigations that were performed during follow‐up visits were different in each study (see the '<a href="./references#CD002200-sec-0136" title="">Characteristics of included studies</a>' tables and <a href="#CD002200-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD002200-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD002200-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD002200-sec-0066"> <h4 class="title">Included studies</h4> <section id="CD002200-sec-0067"> <h5 class="title">Similarities and differences between the included studies</h5> <p>Thirteen of the 19 studies were multicentred (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>). We identified one cluster‐RCT (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>). </p> <section id="CD002200-sec-0068"> <h6 class="title">Participants</h6> <p>Eleven of the 19 studies included Dukes' stage A, B, and C colon and rectal cancer (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>). Six studies excluded Dukes' A participants (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>), two studies excluded participants with rectal cancer (<a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>), and one study included only rectal cancer participants (<a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>). <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> included some participants with completely resected Stage IV disease. </p> </section> <section id="CD002200-sec-0069"> <h6 class="title">Interventions</h6> <p>The studies can be grouped into the following areas of assessment:</p> <p> <ol id="CD002200-list-0012"> <li> <p>'dose' of follow‐up: more visits and tests versus fewer visits and tests (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>); </p> </li> <li> <p>formal follow‐up versus minimal/no follow‐up (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>); </p> </li> <li> <p>more liver imaging versus less liver imaging (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>); </p> </li> <li> <p>CEA versus no CEA (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>); </p> </li> <li> <p>setting for follow‐up (where frequency of visits and tests were identical in both arms): GP‐led follow‐up (<a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>), or nurse‐led follow‐up (<a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>), compared with surgeon‐led follow‐up; </p> </li> <li> <p>usual follow‐up care was supplemented by provision of survivorship educational materials, a survivorship care plan, end of treatment consultation and subsequent phone calls (<a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>). </p> </li> </ol> </p> <p>The included studies did not assess the quality of histopathology.</p> </section> <section id="CD002200-sec-0070"> <h6 class="title">Outcomes</h6> <p> <ol id="CD002200-list-0013"> <li> <p>Fifteen RCTs reported overall survival (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). </p> </li> <li> <p>Eleven RCTs reported colorectal cancer‐specific survival, measured from the time of randomisation in the study ((<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). </p> </li> <li> <p>Sixteen RCTs reported relapse‐free survival, measured from the time of randomisation in the study (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). </p> </li> <li> <p>Thirteen RCTs reported salvage surgery, that is, surgery performed with curative intent for relapse of colorectal cancer (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). </p> </li> <li> <p>Seven RCTs reported interval recurrences, relapse of colorectal cancer detected between follow‐up visits or symptomatic recurrences (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). </p> </li> <li> <p>Seven RCTs assessed quality of life (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>). </p> <ol id="CD002200-list-0014"> <li> <p><a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a> used a Dutch version of the Cancer Worry Scale (<a href="./references#CD002200-bbs2-0050" title="CustersJ , Van denBergSW , VanLaarhovenHW , BelikerEM , GielissenMF , PrinsJB , et al. The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. Cancer Nursing2014;37(1):E44‐50. ">Custers 2014</a>), measured participant attitudes to follow‐up using a validated tool (<a href="./references#CD002200-bbs2-0091" title="StiggelboutAM , DeHaesJC , VreeR , Van deVeldeCJ , BruijninckxCM , VanGroningenK , et al. Follow‐up of colorectal cancer patients: quality of life and attitudes towards follow‐up. British Journal of Cancer1997;75(6):914‐20. ">Stiggelbout 1997</a>), and reported using the Hospital Anxiety Depression Scale (HADS; <a href="./references#CD002200-bbs2-0104" title="ZigmondAS , SnaithRP . The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica1983;67(6):361‐70. ">Zigmond 1983</a>). </p> </li> <li> <p><a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a> used SF‐36 and validated scales (EORTC QLQ C‐30 (European Organization for Research and Treatment of Cancer quality of life questionnaire; <a href="./references#CD002200-bbs2-0033" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85:365‐76. ">Aaronson 1993</a>)) and reported using the HADS (<a href="./references#CD002200-bbs2-0104" title="ZigmondAS , SnaithRP . The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica1983;67(6):361‐70. ">Zigmond 1983</a>). </p> </li> <li> <p><a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> used the 12‐item short version (SF‐12) of SF‐36 (<a href="./references#CD002200-bbs2-0037" title="ApoloneG , MosconiP . The Italian SF‐36 Health Survey: translation, validation and norming. Journal of Clinical Epidemiology1998;51(11):1025‐36. ">Apolone 1998</a>; <a href="./references#CD002200-bbs2-0059" title="GandekB , WareJE , AaronsonNK , ApoloneG , BjornerJB , BrazierJE , et al. Cross‐validation of item selection and scoring for the SF‐12 Health Survey in nine countries: results form the IQOLA Project. International Quality of Life Assessment. Journal of Clinical Epidemiology1998;51(11):1171‐8. ">Gandek 1998</a>), which was validated in the Italian population, and the Psychological General Well‐Being (PGWB) Index (<a href="./references#CD002200-bbs2-0054" title="DupuyH . The Psychological General Well‐Being (PGWB) Index. In: WengerN , MattsonM , FurbergD , ElinsonJ editor(s). Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing, 1984. ">Dupuy 1984</a>). </p> </li> <li> <p><a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a> used the Nottingham Health Profile (<a href="./references#CD002200-bbs2-0036" title="AndersonRT , AaronsonNK , BullingerM , McBeeWL . A review of the progress towards developing health‐related quality of life instruments for international clinical studies and outcomes research. PharmacoEconomics1996;10(4):336‐55. ">Anderson 1996</a>; <a href="./references#CD002200-bbs2-0067" title="HuntSM , McKennaSP , McEwenJ , BackettEM , WilliamsJ , PappE . A quantitative approach to perceived health status: a validation study. Journal of Epidemiology and Community Health1980;34(4):281‐6. ">Hunt 1980</a>). </p> </li> <li> <p><a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> used validated scales EORTC QLQ C‐30 (European Organization for Research and Treatment of Cancer quality of life questionnaire; <a href="./references#CD002200-bbs2-0033" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85:365‐76. ">Aaronson 1993</a>) and EQ‐5D (EuroQol five dimensions questionnaire; <a href="./references#CD002200-bbs2-0053" title="DolanP . Modeling valuations for EuroQol health states. Medical Care1997;35:1095‐108. ">Dolan 1997</a>); </p> </li> <li> <p><a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a> assessed psychological distress using the Brief Symptom Inventory 18 (BSI‐18; <a href="./references#CD002200-bbs2-0103" title="ZaboraJ , BrintzenhofeSzocK , JacobsenP , CurbowB , PiantadosiS , HookerC , et al. A new psychosocial screening instrument for use with cancer patients. Psychosomatics2001;42:241‐6. ">Zabora 2001</a>), survivors' unmet needs using Cancer Survivors' Unmet Need measure (CaSUN; <a href="./references#CD002200-bbs2-0066" title="HodgkinsonK , ButowP , HuntGE , PendleburyS , HobbsKM , LoSK , et al. The development and evaluation of a measure to assess cancer survivor's unmet supportive care needs; the CaSUN (Cancer Survivors Unmet Needs Measure). Psycho‐oncology2007;16:796‐804. ">Hodgkinson 2007</a>), health‐related quality of life using EORTC QLQ C‐30 (<a href="./references#CD002200-bbs2-0033" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85:365‐76. ">Aaronson 1993</a>), and the EORTC QLQ CR‐29 (<a href="./references#CD002200-bbs2-0101" title="WhistanceRN , ConroyT , ChieW , CostantiniA , SezerO , KollerM , et al. European Organisation for the Research and Treatment of Cancer Quality of Life Group. Clinical and psychometric validation of the EORTC QLQ‐CR29 questionnaire module to assess health‐related quality of life in patients with colorectal cancer. European Journal of Cancer2009;45(17):3017‐26. [DOI: 10.1016/j.ejca.2009.08.014.] ">Whistance 2009</a>). </p> </li> <li> <p><a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a> reported the short form (SF)‐12 Physical and Mental Health component (<a href="./references#CD002200-bbs2-0100" title="WareJ , KosinskiM , KellerS . SF‐12: How to Score the SF‐12 Physical and Mental Health Summary Scales. 2nd Edition. Boston Massachusetts: The Health Institute, New England Medical Centre, 1995. ">Ware 1995</a>), and reported using the HADS (<a href="./references#CD002200-bbs2-0104" title="ZigmondAS , SnaithRP . The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica1983;67(6):361‐70. ">Zigmond 1983</a>). </p> </li> </ol> </li> <li> <p><a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> and <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> reported harms. </p> </li> <li> <p>Six studies evaluated costs of surveillance including investigations (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>). <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> and <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a> performed cost‐minimisation analyses. </p> </li> </ol> </p> <p>See <a href="./references#CD002200-sec-0136" title="">Characteristics of included studies</a>. </p> <p>Study accrual dates spanned over three decades. <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; and <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a> accrued in the 1980s and 1990s. <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; and <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> accrued participants in the 1990s and early 2000s. <a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; and <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> accrued participants from 2003 to 2012. </p> <p>The variety of investigations used across the studies may affect the applicability of results. For example, <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; and <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a> did not use CT scanning, while <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> used PET/CT. </p> </section> </section> </section> <section id="CD002200-sec-0071"> <h4 class="title">Excluded studies</h4> <p>For this update, we applied the current recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> with respect to excluded studies and only classified studies as excluded if they were those that one might reasonably expect could have been eligible for inclusion. </p> <p>We excluded four studies (see the '<a href="./references#CD002200-sec-0137" title="">Characteristics of excluded studies</a>' tables). <a href="./references#CD002200-bbs2-0022" title="SanoY , FujiiT , OdaY , MatsudaT , KozuT , KudoS , et al. A multicenter randomized controlled trial designed to evaluate follow‐up surveillance strategies for colorectal cancer: the Japan Polyp Study. Digestive Endoscopy2004;16(4):376‐8. ">Sano 2004</a> was not eligible because participants did not have colorectal cancer. <a href="./references#CD002200-bbs2-0021" title="NCT00182234 . SONICS ‐ Effectiveness of Specialist Oncology Nursing. clinicaltrials.gov/ct2/show/study/NCT00182234?term=NCT00182234&amp;rank=1 (accessed 23 July 2018). SussmanJ , BainbridgeD , WhelanTJ , BrazilK , ParpiaS , WiernikowskiJ , et al. Evaluation of a specialized oncology nursing supportive care intervention in newly diagnosed breast and colorectal cancer patients following surgery: a cluster randomized trial. Supportive Care in Cancer2018;26(5):1533‐41. ">NCT00182234</a> included participants with both breast and colorectal cancer and did not analyse them separately. Participants in <a href="./references#CD002200-bbs2-0023" title="SerranoP , GuC , HusienM , JalinkD , MartelG , TsangME , et al. Effect of PET‐CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: the long‐term results of a randomized controlled trial. Annals of Surgical Oncology. 2018; Vol. 25:1S. ">Serrano 2018</a> had liver metastases, so were not eligible for inclusion in this review. </p> </section> </section> <section id="CD002200-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>There was complete concordance between review authors regarding the evaluation of study methodology (<a href="#CD002200-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD002200-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD002200-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <section id="CD002200-sec-0073"> <h4 class="title">Allocation</h4> <p>Although all of the studies were reported to be randomised, only two explicitly reported that they concealed the allocation of participants to study groups (<a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>). We found that none of the studies were at high risk of bias with respect to allocation; we judged them all to be at low (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>) or unclear risk of bias (<a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>). </p> </section> <section id="CD002200-sec-0074"> <h4 class="title">Blinding</h4> <p>Participant or clinician blinding was not possible. We judged one study to be at high risk of bias for blinding of participants ( <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). One study used independent radiologists who were blinded to study group allocation to assess CT scans (<a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>). We judged three studies to be at high risk of bias for blinding of outcome assessors (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). Most studies were at low risk of bias for blinding <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>;<a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a> and five were at unclear risk of bias (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>). </p> </section> <section id="CD002200-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>Eight studies ensured that they obtained outcome data from more than 80% of the participants. <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a> obtained outcome data for 77% of the participants. All studies conducted intention‐to‐treat analyses. We judged one study to be at high risk of bias for incomplete outcome data (<a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>). Two studies examined compliance with the follow‐up regimen (<a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>), but no study fully assessed contamination. Most studies (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>) were at low risk of attrition bias, four studies were unclear risk of attrition bias (<a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). </p> </section> <section id="CD002200-sec-0076"> <h4 class="title">Selective reporting</h4> <p>We did not have access to the protocols for most studies (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>), so we judged them to be at unclear risk of bias. With more information available we judged <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a> and <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a> to be at low risk of bias for this domain (see <a href="./references#CD002200-sec-0136" title="">Characteristics of included studies</a>). We judged one study at high risk of bias for selective reporting (<a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>). </p> </section> <section id="CD002200-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find other sources of bias (including inadequate follow‐up duration and baseline imbalances on study populations). One study was stopped early (<a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>), but we did not feel this was likely to introduce bias. </p> <section id="CD002200-sec-0078"> <h5 class="title">Overall survival</h5> <p>We judged four studies contributing data to this outcome to be at high risk of bias because they did not mention blinding (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). We did not feel this represented any risk of bias for this objective outcome. We deemed three studies at high risk of bias for allocation concealment, <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>, and attrition bias, <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>, but because they contributed in total 17.2% of study weight, we did not feel that we needed to downgrade for risk of bias. </p> </section> <section id="CD002200-sec-0079"> <h5 class="title">Colorectal cancer‐specific survival</h5> <p>We judged <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a> to be at high risk of attrition bias because the study authors potentially excluded 15% of the participants randomised without explaining to which study arm they belonged. <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> was at high risk of bias for lack of blinding of outcome assessors. These two studies contributed in total 11.9% of study weight for this outcome. <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a> and <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a> did not mention blinding and probably did not ensure it (this represented 41% of the events contributing to this outcome). Because this could cause ascertainment bias for cause of death, we downgraded evidence quality for colorectal cancer‐specific survival for risk of bias. </p> </section> <section id="CD002200-sec-0080"> <h5 class="title">Relapse‐free survival</h5> <p>For this outcome, <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a> and <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> (which contributed 383/1340 (28%) of the events) did not mention blinding. We judged both <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> and <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> at high risk of bias for lack of blinding, but we did not downgrade, because fewer than 30% of events were contributed from studies deemed at high risk of bias. </p> </section> <section id="CD002200-sec-0081"> <h5 class="title">Salvage surgery</h5> <p>We judged <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> to be at high risk of bias for allocation concealment. We also deemed three other studies contributing to this outcome to be at high risk of bias: <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a> and <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> for lack of blinding of outcome assessment, <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a> for incomplete outcome reporting, and <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> further did not blind participants and personnel. We did not downgrade for risk of bias despite these limitations, because <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> contributed only 11/526 (0.05%) of the events for this outcome, lack of blinding was unlikely to have affected the outcome reporting of salvage surgery, and the incomplete outcome reporting in <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a> was related to other outcomes. </p> </section> <section id="CD002200-sec-0082"> <h5 class="title">Interval recurrences</h5> <p>We did not downgrade this outcome for risk of bias. We judged <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a> to be at low risk of bias for all domains. We judged both <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> and <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> to be at high risk of bias for the domain of blinding, but this was because blinding was not mentioned in <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>, and in <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>, there were prespecified follow‐up schedules. We did not downgrade this outcome for risk of bias (<a href="#CD002200-sec-0072">Risk of bias in included studies</a> and <a href="./full#CD002200-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> <section id="CD002200-sec-0083"> <h3 class="title" id="CD002200-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD002200-tbl-0001"><b>Summary of findings for the main comparison</b> Intensive follow‐up compared to less intensive follow‐up for patients treated for colorectal cancer with curative intent</a> </p> <section id="CD002200-sec-0084"> <h4 class="title">1. Primary outcome</h4> <section id="CD002200-sec-0085"> <h5 class="title">1.1 Overall survival</h5> <p>We report on 1453 deaths in 12,528 participants in 15 studies. Intensive follow‐up versus less intense follow‐up for participants treated with curative intent for colorectal cancer makes little or no difference to overall survival (HR 0.91, 95% CI 0.80 to 1.04; 15 studies, 12,528 participants). We found no evidence of heterogeneity: I² = 18%, P = 0.25. In absolute terms, the average effect of intensive follow‐up on overall survival was 24 fewer deaths per 1000 participants, but the true effect could lie between 60 fewer to 9 more per 1000 participants. The GRADE assessment of evidence quality for this outcome was high. The funnel plot did not show evidence of small study effect (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="#CD002200-fig-0003">Figure 3</a>)<i>.</i> </p> <div class="figure" id="CD002200-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.1 overall survival" data-id="CD002200-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.1 overall survival </p> </div> </div> </div> <section id="CD002200-sec-0086"> <h6 class="title">Subgroup analyses</h6> <p> <ol id="CD002200-list-0015"> <li> <p>We compared studies comparing follow‐up provided by different health professionals. Formal testing for subgroup differences was negative (Chi² = 0.40; P = 0.53; I² = 0%) when we compared those studies that used different settings with GP‐ or nurse‐led follow‐up (<a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>), with those set in hospitals (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-fig-0012" title="">Analysis 1.7</a>). </p> </li> <li> <p>In studies that compared more visits and tests with fewer visits and tests (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), versus studies that compared follow‐up with minimal or no follow‐up (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>), formal testing for subgroup differences was negative (Chi² = 0.34; P = 0.56 ; I² = 0 %; <a href="./references#CD002200-fig-0013" title="">Analysis 1.8</a>). </p> </li> <li> <p>In studies using CEA in the intensive follow‐up regimen (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>) versus those studies that did not use CEA (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>), formal testing revealed no evidence of differences between the subgroups (Chi² = 0.15 ; P = 0.7, I² = 0% (<a href="./references#CD002200-fig-0014" title="">Analysis 1.9</a>). </p> </li> <li> <p>We compared studies using CT in the intensive follow‐up regimen (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>) versus those that did not use CT (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>). Formal statistical testing revealed no evidence of differences between the subgroups (Chi² = 0.31; P = 0.58; I² = 0% (<a href="./references#CD002200-fig-0015" title="">Analysis 1.10</a>) </p> </li> <li> <p>We compared studies using frequent CT scans in the intervention arm (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>) versus the use of two or fewer CT scans in the control arm (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>) (<a href="./references#CD002200-fig-0016" title="">Analysis 1.11</a>). Formal statistical testing revealed no evidence of differences between the subgroups (Chi² = 0.99; P = 0.32: I² = 0%). </p> </li> </ol> </p> </section> <section id="CD002200-sec-0087"> <h6 class="title">Sensitivity analyses</h6> <p>Our findings for the outcome of overall survival were robust to sensitivity analyses.</p> <p> <ol id="CD002200-list-0016"> <li> <p>Excluding studies at high risk of bias for this outcome (<a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>), we found no statistical evidence of a survival advantage for the comparison of intensive versus less intensive follow‐up (HR 0.97, 95% CI 0.86 to 1.08). We found no heterogeneity: I² = 0%; P = 0.68, The GRADE assessment of evidence quality for this outcome was high. </p> </li> <li> <p>Excluding six studies on the basis of study age (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>), we found no statistical evidence of a survival advantage for the comparison of intensive versus less intensive follow‐up (HR 0.98, 95% CI 0.84 to 1.15; <a href="./references#CD002200-fig-0006" title="">Analysis 1.1</a>). We found little evidence of heterogeneity: I² = 18%; P = 0.28. The GRADE assessment of evidence quality for this outcome was high. </p> </li> <li> <p>Excluding one study where the intensity of the follow‐up in the 'intensive' arm was similar to that in the control arm of other studies (<a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>), we found no evidence of a clinically meaningful effect on overall survival (HR 0.92, 95% CI 0.81 to 1.05). We found no evidence of heterogeneity: I² = 20%; P = 0.24. The GRADE assessment of evidence quality for this outcome was high. </p> </li> </ol> </p> </section> </section> </section> <section id="CD002200-sec-0088"> <h4 class="title">2. Secondary outcomes</h4> <section id="CD002200-sec-0089"> <h5 class="title">2.1 Colorectal cancer‐specific survival</h5> <p>We were able to report on 925 colorectal cancer deaths in 11,771 participants enrolled in 11 studies; 99.6% had a median follow‐up of greater than 48 months. We found that intensive versus less intensive follow‐up probably makes little or no difference to colorectal cancer‐specific survival (HR 0.93, 95% CI 0.81 to 1.07). We found no evidence of heterogeneity: I² = 0%, P = 0.57 (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-fig-0007" title="">Analysis 1.2</a>). </p> <p>In absolute terms, the average effect of intensive follow‐up on colorectal cancer‐specific survival was five fewer colorectal cancer‐specific deaths per 1000 participants, but the true effect could lie between 14 fewer to five more per 1000 participants. The GRADE assessment of evidence quality for this outcome was moderate, we downgraded once for risk of bias<i>.</i> The funnel plot did not show evidence of small study effect (<a href="#CD002200-fig-0004">Figure 4</a>)<i>.</i> </p> <div class="figure" id="CD002200-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.2 colorectal cancer‐specific survival" data-id="CD002200-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.2 colorectal cancer‐specific survival </p> </div> </div> </div> <section id="CD002200-sec-0090"> <h6 class="title">Sensitivity analyses</h6> <p>Our findings for the outcome of colorectal cancer‐specific survival were robust to the following sensitivity analyses. </p> <p> <ol id="CD002200-list-0017"> <li> <p>Excluding studies at high risk of bias for this outcome (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), we found no statistical evidence of an effect on colorectal cancer‐specific survival (HR 0.90, 95% CI 0.76 to 1.06) and no evidence of heterogeneity: I² = 0%; P = 0.43. </p> </li> <li> <p>We found no statistical evidence of study age having an effect (HR 0.91, 95% CI 0.67 to 1.23) and no evidence of heterogeneity: I² = 30%; P = 0.22 (excluding <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>). </p> </li> </ol> </p> </section> </section> <section id="CD002200-sec-0091"> <h5 class="title">2.2 Relapse‐free survival</h5> <p>We were able to report on 2254 relapses in 8047 participants enrolled in 16 studies, with a median follow‐up of greater than 48 months for 97.9% of participants studied (<a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-fig-0008" title="">Analysis 1.3</a>). </p> <p>We found intensive follow‐up versus less intense follow‐up makes little or no difference to relapse‐free survival (HR 1.05, 95% CI 0.92 to 1.21). The CIs excluded both clinically meaningful benefits and harms. We found no evidence of heterogeneity: I² = 41%, P = 0.05. </p> <p>The funnel plot did not show evidence of small‐study effect (<a href="#CD002200-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD002200-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.3 relapse‐free survival" data-id="CD002200-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.3 relapse‐free survival </p> </div> </div> </div> <p>The average effect of intensive follow‐up on relapse‐free survival was 12 more relapses per 1000 participants, but the true effect could lie between 19 fewer and 48 more per 1000 participants. The GRADE assessment of evidence quality for this outcome was high<i>.</i> </p> <section id="CD002200-sec-0092"> <h6 class="title">Sensitivity analyses</h6> <p>Our findings for the outcome of relapse‐free survival were robust to the following sensitivity analyses. </p> <p> <ol id="CD002200-list-0018"> <li> <p>Excluding studies at high risk of bias for this outcome (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), we found no statistical evidence of an effect (HR 1.13, 95% CI 0.96 to 1.33) and no clear evidence of heterogeneity: I² = 40%; P = 0.08. </p> </li> <li> <p>With regard to study age (excluding <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>), we found no statistical evidence of an effect (HR 1.05, 95% CI 0.79 to 1.40) and little evidence of heterogeneity: I² = 30%; P = 0.21. </p> </li> </ol> </p> </section> </section> <section id="CD002200-sec-0093"> <h5 class="title">2.3 Salvage surgery</h5> <p>We were able to report on 457 episodes of salvage surgery in 5157 participants enrolled in 13 studies, with a follow‐up duration of greater than 48 months in 90.6% of participants studied (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-fig-0009" title="">Analysis 1.4</a>). </p> <p>We found the use of salvage surgery increased with intensive follow‐up for colorectal cancer (RR 1.98, 95% CI 1.53 to 2.56). The CIs included a range of clinically significant increases in salvage surgery. We found some non‐significant evidence of heterogeneity: I² = 31%; P = 0.14. </p> <p>The funnel plot did not show evidence of small‐study effect (see <a href="#CD002200-fig-0005">Figure 5</a>). </p> <p>In absolute terms, the effect of intensive follow‐up on salvage surgery was 60 more episodes of salvage surgery per 1000 participants, but the true effect could lie between 33 to 96 more episodes per 1000 participants. The GRADE assessment of evidence quality for this outcome was high. </p> <section id="CD002200-sec-0094"> <h6 class="title">Sensitivity analyses</h6> <p>Our findings for the outcome of salvage surgery were robust to the following sensitivity analyses. </p> <p> <ol id="CD002200-list-0019"> <li> <p>Excluding studies at high risk of bias for this outcome (<a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), we found some non‐significant heterogeneity (RR 2.03, 95% CI 1.53 to 2.69; I² = 33%; P = 0.15). </p> </li> <li> <p>With regard to study age we found that when we excluded the older studies (<a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a>), there was less heterogeneity (RR 2.04, 95% CI 1.35 to 3.09; I² = 25%; P = 0.25). </p> </li> </ol> </p> </section> </section> <section id="CD002200-sec-0095"> <h5 class="title">2.4 Interval (symptomatic) recurrences</h5> <p>We found 376 interval recurrences reported in 3933 participants enrolled in seven studies, with a median follow‐up duration of greater than 48 months for 100% of participants studied (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>; <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>; <a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>; <a href="./references#CD002200-fig-0010" title="">Analysis 1.5</a>). There was an appreciable decrease in the number of interval recurrences (RR 0.59, 95% CI 0.41 to 0.86). The CIs included a range of clinically significant decreases in interval recurrences (<a href="./references#CD002200-fig-0010" title="">Analysis 1.5</a>). We detected heterogeneity: I² = 66%; P = 0.007. </p> <p>Intensive follow‐up was associated with fewer interval recurrences: 52 fewer per 1000 participants; the true effect is between 18 and 75 fewer per 1000 participants. The GRADE assessment of quality of evidence was moderate, we downgraded once for risk of bias. </p> <section id="CD002200-sec-0096"> <h6 class="title">Sensitivity analyses</h6> <p>Our findings were robust to the following sensitivity analyses.</p> <p> <ol id="CD002200-list-0020"> <li> <p>Excluding studies at high risk of bias for this outcome (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>), we found evidence of heterogeneity (RR 0.61, 95% CI 0.37 to 1.02; I²= 75%; P = 0.003). </p> </li> <li> <p>With regard to study age (excluding <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a>; <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>), we found no evidence of heterogeneity (RR 0.42, 95% CI 0.32 to 0.56; I² = 0%; P = 0.81). </p> </li> </ol> </p> </section> </section> <section id="CD002200-sec-0097"> <h5 class="title">2.5 Quality of life</h5> <p><a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a> found no significant differences between the two groups in terms of attitude to follow‐up, fear of recurrence, HADS score and Cancer Worry score, and there was no detectable burden or improvement in psychological burden associated with intensification of follow‐up. </p> <p><a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> found no clinically significant differences among the three main quality‐of‐life scales (SF‐12 mental component, SF‐12 physical component, and PGWB Index) between the two study arms. </p> <p><a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a> reported the influence of different follow‐up strategies on quality of life for 350 out of 597 Danish participants. They reported a small increase in quality of life (P &lt; 0.05), as measured by the Nottingham Health Profile, associated with more frequent follow‐up visits compared with virtually no follow‐up. </p> <p><a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> reported no significant effect on quality of life for the main outcome measures. They reported significant effects in favour of GP‐led follow‐up for EORTC QLQ‐C30 for role functioning (P = 0.02), emotional functioning (P = 0.01), and pain (P = 0.01). They did not report any significant differences in global health status. </p> <p><a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a> reported that psychological distress was similar between the two groups (difference 0.2, 95% CI −2.5 to 2.9) with the prespecified clinically meaningful difference of 0.42 (figures from the text). DIfferences between unmet needs, information needs and health‐related quality of life were not clinically significant. The intervention group were more satisfied with their care, but the median scores were similar (see <a href="./references#CD002200-sec-0136" title="">Characteristics of included studies</a>). </p> <p><a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a> assessed depression and anxiety, quality of life, and participant satisfaction in a cohort of participants randomised to follow‐up of their colon cancer in different settings (see <a href="#CD002200-sec-0066">Included studies</a>). They found that the study participants remained in the normal range for depression and anxiety with no difference between the two groups at either 12 months or 24 months. Study participants (in each arm) had reduced physical quality of life at baseline, which improved as the study progressed, but there were no significant differences between the two groups. There were no differences between the two groups on the participant satisfaction scale, and both groups reported high levels of satisfaction with their care. </p> <p>More intensive follow‐up probably makes little or no difference to quality of life (moderate‐quality evidence). The data were not available in a form that allowed analysis. </p> </section> <section id="CD002200-sec-0098"> <h5 class="title">2.6 Harms (colonoscopy complications)</h5> <p>Two studies reported adverse events associated with follow‐up (<a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). Three perforations and four gastrointestinal haemorrhages (requiring transfusion) were reported from a total of 2292 (0.3%) colonoscopies. Data from <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> were not available in a form that allowed analysis. Intensive follow‐up may increase the complications (perforation or haemorrhage) from colonoscopies (RR 7.30, 95% CI 0.75 to 70.69); one study, 326 participants) (<a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>) Analysis 1.6; <a href="./full#CD002200-tbl-0001">summary of findings Table for the main comparison</a>). GRADE evidence quality was very low, downgraded for risk of bias related to lack of blinding, reporting bias and imprecision. </p> </section> <section id="CD002200-sec-0099"> <h5 class="title">2.7 Costs of surveillance</h5> <p><a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> found the cost per participant for 24 months' follow‐up was GPB 9889 for surgeon‐led follow‐up and GBP 8233 for GP‐led follow‐up (P &lt; 0.001 (figures from text)). </p> <p><a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a> demonstrated that although the cost of intensive follow‐up was higher, when resectability of recurrences was considered, the cost per resectable recurrence was lower in the intensively followed group. </p> <p><a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> provided risk‐adapted follow‐up based on prognostic factors prospectively identified, and the study authors commented that risk‐adapted follow‐up reduced costs for those with a better prognosis. </p> <p>In <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> the intensive arm cost significantly more than the control arm (P &lt; 0.0033 (figure from text)). </p> <p><a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a> found no difference in costs. </p> <p>Costs were assessed in <a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>, but have not yet been reported. </p> <p>In summary, limited data suggests that the cost of more intensive follow‐up may be increased in comparison with less intense follow‐up, but the cost of surgery for resectable recurrence may be reduced. GRADE evidence quality was low, being downgraded for imprecision. The data were not available in a form that allowed analysis. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002200-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002200-sec-0100">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002200-sec-0173">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002200-sec-0100"></div> <p>The results of our review suggest that there is no overall survival benefit for intensifying the follow‐up of participants after curative surgery for colorectal cancer. The analyses did not show a significant difference in the incidence of recurrence between the participants in the intensively followed groups and the control groups. However, significantly more surgical procedures for recurrence were performed in the experimental arms of the studies. Recurrences in the more intensively followed groups may have been detected earlier allowing for effective salvage treatments, but this did not lead to better overall survival. </p> <p>Each study follow‐up strategy combined a number of different components, including frequency of visits, type of clinical assessment, types and frequency of tests, and the setting in which follow‐up was conducted (see <a href="#CD002200-tbl-0002">Table 1</a>). No study compared the addition of one specific intervention, and the feasibility of comparing strategies with a variety of components and varying complexity becomes problematic. The use of liver imaging does not appear to be associated with improved survival. A specific variation across the studies was the intensity of follow‐up. For example, the follow‐up intensity in the intensively followed group in <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a> was similar to the intensity of follow‐up in the control groups of other studies in the review (<a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a>; <a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a>; <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>). Therefore, it was not possible to extract from these data a precise indication of the optimal combinations of frequency, type, and setting for follow‐up investigations for these participants. Our findings were robust to sensitivity analysis when excluding <a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a>. </p> <div class="table" id="CD002200-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>More intensive follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Less intensive follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Studies comparing more visits and tests versus fewer visits and tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 2‐monthly year 1‐3, then 3‐monthly year 4‐5</p> <p>Clinic visits 12‐monthly year 1‐3</p> <p>CT CAP 12 monthly for 3 years</p> <p>CXR and liver US annually year 1‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 3‐6‐monthly year 1‐3, 12 monthly year 4‐5</p> <p>Clinic visits 6‐monthly year 1‐3, 12 monthly year 4‐5</p> <p>CXR and liver US 6‐monthly year 1‐3, 12‐monthly year 4‐5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Office visits at 4, 8, 12, 16, 20, 24, 30, 36, 42, 48, and 60 months and history and clinical examination, FBC, CEA, and CA 19‐9 </p> <p>Colonoscopy and CXR at 12, 24, 36, 48, and 60 months</p> <p>Liver US at 4, 8, 12, 16, 24, 36, 48, and 60 months</p> <p>For rectal participants, pelvic CT at 4, 12, 24, and 48 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Office visits at 4, 8, 12, 16, 20, 24, 30, 42, 48, and 60 months, including history, examination, and CEA </p> <p>Colonoscopy at 12 and 48 months</p> <p>Liver US at 4 and 16 months</p> <p>Rectal cancer participants in addition had rectoscopy at 4 months, CXR at 12 months, and liver US at 8 and 16 months. A single pelvic CT was allowed if a radiation oncologist required it as baseline following adjuvant treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits at 6, 12, 18, 30, 36, 48, 60, 120, 150, and 180 months after radical surgery<br/> Examinations included medical history, clinical examination, DRE, gynaecological examination, Haemoccult‐II test, colonoscopy, CXR, haemoglobin level, erythrocyte sedimentation rate, and liver enzymes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits at 60, 120, and 180 months</p> <p>Examinations included medical history, clinical examination, DRE, gynaecological examination, Haemoccult‐II test, colonoscopy, CXR, haemoglobin level, erythrocyte sedimentation rate, and liver enzymes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with rectal or sigmoid cancers had flexible sigmoidoscopy with video imaging every 3 months, colonoscopy at 3 months (if it had not been done preoperation), then annually. Liver US and primary site at 6 months, then annually </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants who had rectal and sigmoid cancers had rigid sigmoidoscopy and barium enema annually </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 months, then annually thereafter. </p> <p>At each visit: clinical examination, US, CEA, and CXR. Annual CT liver and colonoscopy were performed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seen at 6 and 12 months, then annually.</p> <p>At each visit, clinical examination, CEA, and US were performed. They had annual CXR, yearly colonoscopy, and CT scan. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>History, examination, and bloods (including CEA), US/CT, CXR, and colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>history, examination, and bloods (including CEA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PET performed at 9 and 15 months and conventional follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FDG PET/CT at 6, 12, 18, 24, 30 and 36 months pus conventional follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional follow‐up: physical examination and laboratory tests (FBC, tumour markers) at 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 months, liver US and CXR at 3, 9, 15, 21, 27, 33 months, CT CAP at 6, 12, 18, 24, 30 and 36 months, colonoscopy at 12 and 36 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse‐led survivorship care package:</p> <p> <ol id="CD002200-list-0021"> <li> <p>educational materials</p> </li> <li> <p>needs assessment</p> </li> <li> <p>survivorship care plan</p> </li> <li> <p>end‐of‐treatment session</p> </li> <li> <p>3 follow‐up phone calls plus usual care</p> </li> </ol> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care defined as: "care according to the treating cancer centre or practitioner's usual practice" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA rise triggered 'second‐look' surgery, with intention to remove any recurrence discovered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA rise did not trigger 'second‐look' surgery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colonoscopy at each visit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colonoscopy at 6 months, 30 months, and 60 months from randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Studies comparing tests and visits with minimal or no follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 1 month postoperatively then CEA, CT chest and abdomen 6, 12, 18, 24, and 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 1 month postoperatively then CEA, CT chest and abdomen 12 and 36 months after surgery </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD002200-list-0022"> <li> <p>CEA testing every 3 months for 2 years, then every 6 months for 3 years with a single CT scan of the CAP if requested at study entry by clinician </p> </li> <li> <p>CT scan of the CAP every 6 months for 2 years, then annually for 3 years, plus colonoscopy at 2 years </p> </li> <li> <p>CEA and CT follow‐up: both blood and imaging as above, plus colonoscopy at 2 years</p> </li> </ol> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No scheduled follow‐up except a single CT scan of the CAP if requested at study entry by a clinician </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐, 6‐, 9‐, 12‐, 15‐, 18‐, 21‐, 24‐, 30‐, 36‐, 42‐, 48‐, and 60‐month clinic visits. Performed at each visit were clinical exam, rigid proctosigmoidoscopy, CEA, alkaline phosphatase, gamma‐glutaryl transferase, faecal haemoglobin, and CXR. Examination of anastomosis (flexible sigmoidoscopy or colonoscopy, as dictated by the lesion) was performed at 9, 21, and 42 months. Colonoscopy was performed at 3, 15, 30, and 60 months. CT of the pelvis was performed at 3, 6, 12, 18, and 24 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No planned follow‐up visits. Participants received written instructions recommending that they leave faecal samples with the district nurse for examination every third month during the first 2 years after surgery then once a year. They were instructed to contact the surgical department if they had any symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yearly CXR, CT of the liver, and colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These investigations were only performed in the control group if indicated on clinical grounds or after screening test abnormality, and at 5 years of follow‐up, to exclude a reservoir of undetected recurrences </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits and serum CEA, abdomen/pelvic US scans, and CXR. Participants with rectal carcinoma had rigid sigmoidoscopy and CXR. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"minimal follow‐up programme performed by physicians"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Studies that assessed effect of setting for follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgeon‐led follow‐up</p> <p>Frequency of follow‐up equal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP‐led follow‐up</p> <p>Frequency of follow‐up equal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgeon‐led follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse‐led follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care setting and environment for follow‐up<br/> Follow‐up guidance was based on current clinical practice, and guidance was provided that suggested follow‐up visits every 3 months for the first 2 years postoperatively, then every 6 months for the next 3 years.<br/> Each visit incorporated asking a list of set questions about symptoms, physical examination, annual faecal occult blood testing, and colonoscopy every 3 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary care setting for follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CA 19‐9:</b> cancer antigen 19‐9; <b>CEA:</b> carcinoembryonic antigen; <b>CAP:</b> chest, abdomen, pelvis; <b>CT:</b> computed tomography; <b>CXR:</b> chest X‐ray; <b>DRE:</b> digital rectal examination; <b>FBC:</b> full blood count; <b>FDG:</b> fluorodeoxyglucose; <b>PET:</b> positron emission tomography; <b>US:</b> ultrasound </p> </td> </tr> </tbody> </table> </div> <p>Most recurrences (about 90%) occur within the initial 36 months after initial therapy for colorectal cancer (<a href="./references#CD002200-bbs2-0086" title="RyukJP , ChoiGS , ParkJS , KimHJ , ParkSY , YoonGS , et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Annals of Surgical Treatment and Research2014;86(3):143‐51. ">Ryuk 2014</a>), so to detect recurrences, follow‐up duration should be at least 36 months for colorectal cancer. Patients with rectal cancer should have longer follow‐up because liver and lung recurrences may be delayed. The use of adjuvant chemotherapy may further delay recurrence (<a href="./references#CD002200-bbs2-0087" title="SadahiroS , SuzukiT , IshikawaK , NakamuraT , TanakaY , MasudaT , et al. Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology2003;50(53):1362‐6. ">Sadahiro 2003</a>). For the outcomes included in this study, median follow‐up duration was greater than 48 months for more than 90% of the participants studied. </p> <p>We presented substantially altered conclusions in the 2016 update of the review (<a href="./references#CD002200-bbs2-0106" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a>). Where we previously reported that "there was evidence that an overall survival benefit at five years exists for patients undergoing more intensive follow up", <a href="./references#CD002200-bbs2-0106" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a> did not confirm these findings. The four new studies included in this updated version of the review (<a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a>; <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a>; <a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a>; <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a>), with an additional 6238 participants, reinforced our findings in <a href="./references#CD002200-bbs2-0106" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a> that there is no overall survival benefit for intensifying the follow‐up of patients after curative surgery for colorectal cancer. </p> <section id="CD002200-sec-0101"> <h3 class="title" id="CD002200-sec-0101">Summary of main results</h3> <p> <ol id="CD002200-list-0023"> <li> <p>Overall survival: the use of intensive versus less intensive follow‐up makes little or no difference after curative treatment (HR 0.91, 95% CI 0.80 to 1.04; <a href="./references#CD002200-fig-0006" title="">Analysis 1.1</a>). </p> </li> <li> <p>Colorectal cancer‐specific survival: the use of intensive versus less intensive follow‐up makes little or no difference after curative treatment (HR 0.93, 95% CI 0.81 to 1.07; <a href="./references#CD002200-fig-0007" title="">Analysis 1.2</a>). </p> </li> <li> <p>Relapse‐free survival: intensive versus less intensive follow‐up makes little or no difference after curative treatment (HR 1.05, 95% CI 0.92 to 1.21; <a href="./references#CD002200-fig-0008" title="">Analysis 1.3</a>). </p> </li> <li> <p>The use of salvage surgery was increased with intensive follow‐up after curative treatment for colorectal cancer (RR 1.98, 95% CI 1.53 to 2.56; <a href="./references#CD002200-fig-0009" title="">Analysis 1.4</a>). </p> </li> <li> <p>Interval (symptomatic) recurrences were probably slightly reduced with intensive follow‐up after curative treatment for colorectal cancer (RR 0.59, 95% CI 0.41 to 0.86; <a href="./references#CD002200-fig-0010" title="">Analysis 1.5</a>). </p> </li> </ol> </p> <section id="CD002200-sec-0102"> <h4 class="title">Quality of life</h4> <p><a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a> found no significant differences between the two groups in terms of attitude to follow‐up, fear of recurrence, HADS score and Cancer Worry score, and there was no detectable burden or improvement in psychological burden associated with intensification of follow‐up. <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> found no clinically significant differences among the three main quality‐of‐life scales (SF‐12 mental component, SF‐12 physical component, and PGWB Index) between the two study arms. <a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a> reported a small increase in quality of life associated with more frequent follow‐up visits compared with virtually no follow‐up. <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> reported no significant effect on quality of life main outcome measures: for EORTC QLQ‐C30, they reported significant effects in favour of GP‐led follow‐up for pain, role functioning, and emotional functioning; they reported no differences in global health status, with intensive follow‐up compared with less intense follow‐up. <a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a> found no clinically meaningful differences in psychological distress, unmet needs, information needs and health‐related quality of life. <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a> found that the study participants remained in the normal range for depression and anxiety with no difference between the two groups at either 12 or 24 months. </p> </section> <section id="CD002200-sec-0103"> <h4 class="title">Harms and costs of surveillance (including investigations)</h4> <p>The studies reported three bowel perforations and four gastrointestinal haemorrhages (requiring transfusion) from a total of 2292 (0.3%) colonoscopies (<a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). </p> <p><a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> found the cost per participant for 24 months' follow‐up was GBP 9889 for surgeon‐led follow‐up and GBP 8233 for GP‐led follow‐up (P &lt; 0.001 (figures from text)). <a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a> demonstrated that although the cost of intensive follow‐up was higher, when they considered resectability of recurrences, the cost per resectable recurrence was lower in the intensively followed group. <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> reported that risk‐adapted follow‐up reduced costs for those with a better prognosis. <a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a> showed no difference in costs. </p> </section> </section> <section id="CD002200-sec-0104"> <h3 class="title" id="CD002200-sec-0104">Overall completeness and applicability of evidence</h3> <p>The evidence we report is directly relevant to the study question.</p> <p>The studies have been accrued over a prolonged time period, during which time there have been significant changes in cancer staging procedures, operative techniques (surgical metastasectomy or ablation of liver metastases), postoperative care, adjuvant therapies, and the investigations available to detect recurrence. Systemic adjuvant therapies and effective palliative chemotherapy drugs are now widely utilised, with significant prolongation of survival rates. All of these factors question the validity of applying the results of early studies to the modern surgical and oncological setting. A sensitivity analysis excluding studies that commenced accrual before 1996 did not however reveal any effect of study age on the outcome of overall survival (HR 0.97, 95% CI 0.74 to 1.28). The lack of benefit from intensive follow‐up persisted despite the inclusion of modern studies that used modern surgical techniques for resection of liver metastases, (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>), and more sensitive investigations to detect recurrence, such as PET scanning (<a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a>). </p> <p>The argument for intensive follow‐up has been up to now based on observational data that reports improved survival after hepatic metastasectomy. We did not find an improvement in overall survival with the use of liver imaging (HR 0.92, 95% CI 0.81 to 1.21). </p> <p>The identified studies are sufficient to address our objectives; future updates of this review are likely to address those outcomes that we cannot yet address in detail, when ongoing studies detail quality of life ( <a href="./references#CD002200-bbs2-0032" title="LepageC , PhelipJ‐M , CanyL , FarouxR , ManfrediS , AinJ‐F . Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Digestive and Liver Disease2015;47(7):529‐31. LepageC , PhelipJM , CanyL , MaillardE , LievreA , ChatellierT , et al. Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer‐PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology2016. NCT00995202 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">SURVEILLANCE</a>), costs (<a href="./references#CD002200-bbs2-0032" title="LepageC , PhelipJ‐M , CanyL , FarouxR , ManfrediS , AinJ‐F . Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Digestive and Liver Disease2015;47(7):529‐31. LepageC , PhelipJM , CanyL , MaillardE , LievreA , ChatellierT , et al. Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer‐PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology2016. NCT00995202 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">SURVEILLANCE</a>; <a href="./references#CD002200-bbs2-0025" title="NCT00199654 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">NCT00199654</a>), and the effects of the addition of PET scanning into follow‐up for these participants (<a href="./references#CD002200-bbs2-0025" title="NCT00199654 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">NCT00199654</a>). </p> <p>We were unable to obtain data for overall survival for the <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> study (despite contacting the authors) because of personnel changes at the institution concerned. </p> <p>The studies included the relevant participant population. The interventions assessed were very inclusive, addressing a variety of 'doses' or intensities of follow‐up, ranging from no follow‐up to intense follow‐up, and evaluated multiple investigations including the use of CT and PET scanning (see <a href="#CD002200-tbl-0002">Table 1</a>). We recognise that there is considerable variation in the intensity of both the intervention and the control arms in the included studies. We feel our decision to pool the studies is vindicated by the lack of important heterogeneity for overall survival (I² = 18%, P = 0.25) and the lack of subgroup effect on overall survival when we explored follow‐up 'dose' and composition. </p> <p>No study addressed any potential psychological harms, anxiety, or distress that may be associated with follow‐up after treatment for colorectal cancer. </p> <p>The studies included in this review did not well report the potential harms (physical, psychological) and costs of follow‐up strategies. Two studies reported harms related to colonoscopy (<a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a>; <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a>). The rate of perforation (4/2292) 0.17% and haemorrhage (3/2292) 0.13 was consistent with other published series (<a href="./references#CD002200-bbs2-0038" title="AraghizadehFY , TimmckeAE , OpelkaFG , HicksTC , BeckDE . Colonoscopic perforations. Diseases of the Colon and Rectum2001;44(5):713‐6. ">Araghizadeh 2001</a>; <a href="./references#CD002200-bbs2-0043" title="BowlesCJ , LeicesterR , RomayaC , SwarbrickE , WilliamsCB , EpsteinO . A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow?. Gut2004;53(2):277‐83. ">Bowles 2004</a>; <a href="./references#CD002200-bbs2-0081" title="RabeneckL , PaszatLF , HilsdenRJ , SaskinR , LeddinD , GrunfeldE , et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology2008;135(6):1899‐1906. ">Rabenek 2008</a>). None of the study reports included specific details of any harms (mortality or morbidity) resulting from investigation or treatment of recurrences. These outcomes should be available in order to fully assess any net benefit or harm of follow‐up. </p> <p>Some researchers have investigated the psychological effects of follow‐up (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>; <a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>; <a href="./references#CD002200-bbs2-0091" title="StiggelboutAM , DeHaesJC , VreeR , Van deVeldeCJ , BruijninckxCM , VanGroningenK , et al. Follow‐up of colorectal cancer patients: quality of life and attitudes towards follow‐up. British Journal of Cancer1997;75(6):914‐20. ">Stiggelbout 1997</a>; <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>). These studies have reported mixed effects on quality‐of‐life measures, but no study has found a deterioration in quality of life. Some form of follow‐up appeared superior to virtually no follow‐up in terms of quality of life (<a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a>). Different settings for follow‐up (GP‐ versus surgeon‐led) did not appear to affect anxiety or depression; both groups had a high and similar level of participant satisfaction (<a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>). Ongoing studies will address the effects of intensifying follow‐up on quality of life in this population (<a href="./references#CD002200-bbs2-0032" title="LepageC , PhelipJ‐M , CanyL , FarouxR , ManfrediS , AinJ‐F . Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Digestive and Liver Disease2015;47(7):529‐31. LepageC , PhelipJM , CanyL , MaillardE , LievreA , ChatellierT , et al. Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer‐PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology2016. NCT00995202 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">SURVEILLANCE</a>). </p> <p>Further research is required into the value that participants place on follow‐up after their curative surgery. Any survival benefit (or lack of benefit) of follow‐up would have to be considered along with the views of participants so that follow‐up programmes are accessible, acceptable, and address all participants' needs and concerns. </p> <p>Little useful data are available from the studies in this review on the cost‐effectiveness of follow‐up in this group of patients treated for non‐metastatic colorectal cancer. It appears that GP‐led follow‐up is cheaper than surgeon‐led follow‐up (<a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a>); risk‐adapted follow‐up is cheaper for those with better prognosis disease (<a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a>), and although the cost of intensive follow‐up is higher, it makes the cost per resectable recurrence lower (<a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a>). Without a better understanding of which of the specific follow‐up interventions is responsible for the improvement in outcomes, it is not possible to even speculate on the potential cost‐effectiveness of any one approach. Investigators have previously tried to project the costs of a single intervention such as CEA testing (<a href="./references#CD002200-bbs2-0039" title="AudisioRA , Setti‐CarraroP , SegalaM , CapkoD , AndreoniB , TiberioG . Follow‐up in colorectal cancer patients: a cost‐benefit analysis. Annals of Surgical Oncology1996;3(4):349‐57. ">Audisio 1996</a>; <a href="./references#CD002200-bbs2-0072" title="MoertelCG , FlemingTR , MacdonaldJS , HallerDG , LaurieJA , TangenC . An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA1993;270(8):943‐7. ">Moertel 1993</a>), and the reported costs have appeared prohibitively large. In contrast, an incremental cost‐effectiveness analysis based on five randomised controlled trials has reported costs of intensive follow‐up, which appear acceptable in the setting of the National Health Service in the UK (<a href="./references#CD002200-bbs2-0083" title="RenehanAG , O'DwyerST , WhynesDK . Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ2004;328(7431):81‐5. ">Renehan 2004</a>), although the study authors do acknowledge a number of limitations of their study. The ongoing PRODIGE study will address the issue of costs so that the relative cost‐effectiveness of follow‐up can be viewed from an economic perspective as well as a clinical one (<a href="./references#CD002200-bbs2-0032" title="LepageC , PhelipJ‐M , CanyL , FarouxR , ManfrediS , AinJ‐F . Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Digestive and Liver Disease2015;47(7):529‐31. LepageC , PhelipJM , CanyL , MaillardE , LievreA , ChatellierT , et al. Effect of 5 years of imaging and CEA follow‐up to detect recurrence of colorectal cancer‐PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology2016. NCT00995202 . Follow‐up care with or without CEA assessments in patients who have undergone surgery for stage II or stage III colorectal cancer [Follow‐up of fully resected stage II or III colorectal cancer. Phase III multicentric prospective randomised study]. clinicaltrials.gov/ct2/show/NCT00995202?term=NCT00995202&amp;rank=1 (first received 14 November 2012). ">SURVEILLANCE</a>). </p> <p>New biomarkers such as circulating tumour DNA are likely be investigated in future follow‐up studies to detect earlier colorectal cancer metastatic spread and recurrence (<a href="./references#CD002200-bbs2-0076" title="OellerichM , SchültzE , BeckJ , KanzowP , PlowmanP , WeissG , et al. Using circulating cell‐free DNA to monitor personalized cancer therapy. Critical Reviews in Clinical Laboratory Science2017;54(3):205‐18. ">Oellerich 2017</a>). </p> </section> <section id="CD002200-sec-0105"> <h3 class="title" id="CD002200-sec-0105">Quality of the evidence</h3> <p>The findings of this review allow robust conclusions, with minimal heterogeneity and low risk of publication bias (based on the use of funnel plots). </p> <section id="CD002200-sec-0106"> <h4 class="title">Overall survival</h4> <p>For the outcome of overall survival, we studied 12,528 participants in 15 studies. We did not downgrade for risk of bias. Outcome assessment was standard in the included studies. We did not downgrade for inconsistency (I² = 18%; P = 0.25) or indirectness: 9054/12,528 (72 %) participants contributing to this outcome were accrued after 2003 (so used modern investigations and surgical salvage techniques). We did not downgrade for imprecision (there were more than 300 events (1453), and the confidence intervals excluded clinically meaningful benefit or harm). We did not downgrade for publication or other bias. The GRADE assessment of evidence quality for this outcome was high<i>.</i> </p> </section> <section id="CD002200-sec-0107"> <h4 class="title">Colorectal cancer‐specific survival</h4> <p>For the outcome colorectal cancer‐specific survival, we studied 11,771 participants in 11 studies. We downgraded because 40% of the events were from studies deemed at high risk of bias for incomplete outcome reporting or lack of blinding. We did not downgrade for inconsistency (I² = 0%; P = 0.57). We did not downgrade for indirectness, despite the long time period over which studies accrued participants; 34% of the participants included in this outcome were enrolled in studies that accrued in the 2000s. We did not downgrade for imprecision (there were more than 300 events (925), and the confidence intervals excluded clinically meaningful benefit or harm). We did not downgrade for publication or other bias. The GRADE assessment of evidence quality for this outcome was moderate<i>.</i> </p> </section> <section id="CD002200-sec-0108"> <h4 class="title">Relapse‐free survival</h4> <p>For the outcome of relapse‐free survival, we studied 8047 participants in 16 studies. We did not downgrade for risk of bias, because fewer than 30% of the events were from studies deemed at high risk of bias from lack of blinding. We did not downgrade for inconsistency (I² = 41 %; P = 0.05); we felt there was unlikely to be meaningful heterogeneity: analysis using the fixed‐effect model gave similar effect magnitude, direction, and 95% CI (HR 1.15, 95% CI 1.05 to 1.25). There was no funnel plot asymmetry, which also helped exclude heterogeneity. We did not downgrade for indirectness, or imprecision (there were more than 300 events (2254), and the confidence intervals excluded clinically meaningful benefit or harm). We did not downgrade for publication or other bias. The GRADE assessment of evidence quality for this outcome was high<i>.</i> </p> </section> <section id="CD002200-sec-0109"> <h4 class="title">Salvage surgery</h4> <p>For the outcome of salvage surgery, we studied 5157 participants in 13 studies. We did not downgrade for risk of bias. We did not downgrade for indirectness, because 1988 of 5854 (33%) of participants contributing to this outcome were enrolled in studies done in the 2000s. There was evidence of precision (with more than 300 events (457) and optimum information size met). While there was some evidence of non‐significant inconsistency (I² = 31%; P = 0.14), we felt that the variation in the intensity of follow‐up across the studies and the prolonged time period for accrual (which allowed for varied surgical techniques and degrees of surgical aggression) explained this because of clinical heterogeneity between the studies, so we did not downgrade for this. Prespecified sensitivity analysis based on study age supported this (I² = 25%; P = 0.25). We did not downgrade for publication bias. The GRADE assessment of evidence quality for this outcome was high. </p> </section> <section id="CD002200-sec-0110"> <h4 class="title">Interval (symptomatic) recurrences</h4> <p>For the outcome of interval recurrences, we studied 3933 participants in seven studies. We downgraded for risk of bias, because 58% of the events came from studies at high risk of bias because of lack of blinding. We did not downgrade for inconsistency (I² = 66%; P = 0.007), because prespecified sensitivity analysis based on study age explained this heterogeneity (I² = 0%; P = 0.81). We did not downgrade for indirectness or imprecision (there were more than 300 events (376)) or publication bias. The GRADE assessment of quality of evidence was moderate. </p> </section> <section id="CD002200-sec-0111"> <h4 class="title">Quality of life</h4> <p>Quality‐of‐life data were not available in a form that allowed analysis, so we did not pool these data. Studies comparing intensive follow‐up to less intensive follow‐up used a variety of scales to assess multiple outcomes. GRADE evidence quality was moderate, downgraded for risk of bias. </p> </section> <section id="CD002200-sec-0112"> <h4 class="title">Harms</h4> <p>For the outcome of harms, we studied 651 participants in two studies. These were rare events (seven events reported in 2292 colonoscopies in two studies). We downgraded for lack of blinding, reporting bias and imprecision, so the GRADE assessment of quality of evidence was very low. </p> </section> <section id="CD002200-sec-0113"> <h4 class="title">Costs</h4> <p>Limited data suggests the cost of more intensive follow‐up is increased in comparison with less intense follow‐up but the cost of surgery for resectable recurrence may be reduced. GRADE evidence quality was low, being downgraded for imprecision (there were fewer than 300 events, OIS was not met and 95% CI could not be estimated). </p> </section> </section> <section id="CD002200-sec-0114"> <h3 class="title" id="CD002200-sec-0114">Potential biases in the review process</h3> <p>The studies included in this review did not report the potential harms of either investigations or salvage treatments. It is possible that investigators excluded participants from study enrolment whom they felt to be at high risk of recurrence; if this did occur, it may have diluted the effect of follow‐up strategies on survival. </p> </section> <section id="CD002200-sec-0115"> <h3 class="title" id="CD002200-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>We identified six published systematic reviews relevant to our question. Our findings differ from those reported by <a href="./references#CD002200-bbs2-0074" title="MokhlesS , MacbethF , FarewellV , FiorentinoF , WilliamsNR , YounesRN , et al. Meta‐analysis of colorectal cancer follow‐up after potentially curative resection. British Journal of Surgery2016;103(10):1259‐67. ">Mokhles 2016</a>; <a href="./references#CD002200-bbs2-0080" title="Pita‐FernándezS , Alhayek‐AíM , González‐MartinC , López‐CalviñoB , Seoane‐PilladoT , Pértega‐DíazS . Intensive follow‐up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta‐analysis. Annals of Oncology Advance Access2014;00:1‐12. ">Pita‐Fernández 2014</a>; <a href="./references#CD002200-bbs2-0082" title="RenehanA , EggerM , SaundersMP , O'DwyerST . Impact on survival of intensive follow‐up after curative resection for colorectal cancer: systematic review and meta‐analysis of randomised trials. BMJ2002;324:813. ">Renehan 2002</a>; and <a href="./references#CD002200-bbs2-0094" title="TjandraJJ , ChanMK . Follow‐up after curative resection of colorectal cancer: a meta‐analysis. Diseases of the Colon and Rectum2007;50(11):1783‐99. ">Tjandra 2007</a>: they found that intensive follow‐up for participants treated with curative intent for colorectal cancer improved survival. The other two systematic reviews did not report a quantitative meta‐analysis (<a href="./references#CD002200-bbs2-0041" title="AugestadKM , RoseJ , CrawhsawB , CooperG , DelaneyC . Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review. World Journal of Gastrointestinal Oncology2014;6(5):104‐11. ">Augestad 2014</a>; <a href="./references#CD002200-bbs2-0042" title="BacaB , BeartRW , EtzioniDA . Surveillance after colorectal cancer resection: a systematic review. Diseases of the Colon and Rectum2011;54(8):1036‐48. ">Baca 2011</a>). See <a href="#CD002200-tbl-0003">Table 2</a>. </p> <div class="table" id="CD002200-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Systematic reviews on topic</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies included</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Search date</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes for overall survival for comparison intensive versus less intensive follow‐up for participants treated with curative intent for colorectal cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0041" title="AugestadKM , RoseJ , CrawhsawB , CooperG , DelaneyC . Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review. World Journal of Gastrointestinal Oncology2014;6(5):104‐11. ">Augestad 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No search date given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not present quantitative meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0042" title="BacaB , BeartRW , EtzioniDA . Surveillance after colorectal cancer resection: a systematic review. Diseases of the Colon and Rectum2011;54(8):1036‐48. ">Baca 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>January 2000 to 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not present quantitative meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002200-bbs2-0080" title="Pita‐FernándezS , Alhayek‐AíM , González‐MartinC , López‐CalviñoB , Seoane‐PilladoT , Pértega‐DíazS . Intensive follow‐up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta‐analysis. Annals of Oncology Advance Access2014;00:1‐12. ">Pita‐Fernández 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>June 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.75 (95% CI 0.66 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002200-bbs2-0082" title="RenehanA , EggerM , SaundersMP , O'DwyerST . Impact on survival of intensive follow‐up after curative resection for colorectal cancer: systematic review and meta‐analysis of randomised trials. BMJ2002;324:813. ">Renehan 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>April 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.81 (95% CI 0.70 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0094" title="TjandraJJ , ChanMK . Follow‐up after curative resection of colorectal cancer: a meta‐analysis. Diseases of the Colon and Rectum2007;50(11):1783‐99. ">Tjandra 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74 (95% CI 0.59 to 0.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>OR:</b> odds ratio; RR: risk ratio </p> </td> </tr> </tbody> </table> </div> <p><a href="./references#CD002200-bbs2-0041" title="AugestadKM , RoseJ , CrawhsawB , CooperG , DelaneyC . Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review. World Journal of Gastrointestinal Oncology2014;6(5):104‐11. ">Augestad 2014</a> searched PubMed and reference lists of published studies (no search date given). They reported no quantitative meta‐analysis for the five studies they included. They commented that recent data did not report a survival advantage (<a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a>), and they suggested that the potential survival benefits of surveillance should be weighed against possible negative effects. </p> <p><a href="./references#CD002200-bbs2-0042" title="BacaB , BeartRW , EtzioniDA . Surveillance after colorectal cancer resection: a systematic review. Diseases of the Colon and Rectum2011;54(8):1036‐48. ">Baca 2011</a> searched PubMed and reference lists (search date: June 2000 to June 2010). They included <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> (Grossman data), <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> and <a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> but did not present a quantitative meta‐analysis. They included both randomised (n = 5) and non‐randomised (n = 11) studies. They concluded that recent literature is inconclusive with respect to the benefit of surveillance for colorectal cancer after curative treatment. The difference in our findings was likely to relate to our more recent search and inclusion of 10 more RCTs. </p> <p><a href="./references#CD002200-bbs2-0074" title="MokhlesS , MacbethF , FarewellV , FiorentinoF , WilliamsNR , YounesRN , et al. Meta‐analysis of colorectal cancer follow‐up after potentially curative resection. British Journal of Surgery2016;103(10):1259‐67. ">Mokhles 2016</a> included seven studies and 3325 participants. Their search was systematic (search date not reported). They excluded non‐English studies. They reported no improvement in survival with intensive follow‐up (HR 0.98, 95% CI 0.87 to 1.11). They excluded <a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> and the review was published before the results of <a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a> and <a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a> were available. Their findings support those we report in this update. </p> <p><a href="./references#CD002200-bbs2-0080" title="Pita‐FernándezS , Alhayek‐AíM , González‐MartinC , López‐CalviñoB , Seoane‐PilladoT , Pértega‐DíazS . Intensive follow‐up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta‐analysis. Annals of Oncology Advance Access2014;00:1‐12. ">Pita‐Fernández 2014</a> included 11 RCTs, with 4055 participants. Their search was limited to four bibliographic databases (search date: June 2014). They reported that overall survival increased with intensive follow‐up (HR 0.75, 95% CI 0.66 to 0.86; see <a href="#CD002200-tbl-0003">Table 2</a>). They included data relating to the <a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> study from an earlier paper with 14 months' median follow‐up, published while the study was still accruing participants (<a href="./references#CD002200-bbs2-0062" title="GrossmannEM , JohnsonFE , VirgoKS , LongoWE , FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. ">Grossman 2004</a>). In addition, they included data from <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> and <a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a>, which we were unable to extract. It appears that the data for overall survival reported for <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> may have been derived from the actuarial survival at five years (reported as percentages). We contacted the study authors for <a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> (detailed in the <a href="#CD002200-sec-0036">Methods</a> section), who informed us that they could not give us any more information than was in the text due to personnel changes. As stated above, it appears that the review authors incorrectly derived the overall survival data from the actuarial survival percentages reported. </p> <p><a href="./references#CD002200-bbs2-0082" title="RenehanA , EggerM , SaundersMP , O'DwyerST . Impact on survival of intensive follow‐up after curative resection for colorectal cancer: systematic review and meta‐analysis of randomised trials. BMJ2002;324:813. ">Renehan 2002</a> included five RCTs and 1342 participants. Their search was systematic (search date: April 2001). They reported improved survival with intensive follow‐up in this setting. Again, the difference in our findings was likely to relate to our more recent search and inclusion of 10 more RCTs. </p> <p><a href="./references#CD002200-bbs2-0094" title="TjandraJJ , ChanMK . Follow‐up after curative resection of colorectal cancer: a meta‐analysis. Diseases of the Colon and Rectum2007;50(11):1783‐99. ">Tjandra 2007</a> included eight RCTs and 2923 participants. Their search was systematic (search date: June 2007). They reported improved survival with intensive follow‐up. Once again, the difference in our findings was likely to relate to our more recent search and inclusion of seven more RCTs. </p> <p>The first iteration of this Cochrane Review also found improved survival in this setting (<a href="./references#CD002200-bbs2-0105" title="JefferyM , HickeyBE , HiderPN . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD002200.pub2] ">Jeffery 2007</a>). The 2016 updated version of the review (<a href="./references#CD002200-bbs2-0106" title="JefferyM , HickeyBE , HiderPN , SeeAM . Follow‐up strategies for patients treated for non‐metastatic colorectal cancer. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD002200.pub3] ">Jeffery 2016</a>), contradicted the previously reported effects of surveillance on survival for participants treated with curative intent for colorectal cancer. This updated version of the review, which now includes data from 19 studies with 13,216 participants, consolidates these conclusions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002200-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD002200-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD002200-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.1 overall survival" data-id="CD002200-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.1 overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.2 colorectal cancer‐specific survival" data-id="CD002200-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.2 colorectal cancer‐specific survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.3 relapse‐free survival" data-id="CD002200-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison 1. Intensive follow‐up versus minimalist follow‐up, outcome: 1.3 relapse‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 1 Overall survival." data-id="CD002200-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 2 Colorectal cancer‐specific survival." data-id="CD002200-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 2 Colorectal cancer‐specific survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 3 Relapse‐free survival." data-id="CD002200-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 3 Relapse‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 4 Salvage surgery." data-id="CD002200-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 4 Salvage surgery.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 5 Interval recurrences." data-id="CD002200-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 5 Interval recurrences.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 6 Harms (colonoscopic complications)." data-id="CD002200-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 6 Harms (colonoscopic complications). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 7 Overall survival SG Healthcare professional." data-id="CD002200-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 7 Overall survival SG Healthcare professional. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt='Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 8 Overall survival SGA "dose" of follow‐up.' data-id="CD002200-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 8 Overall survival SGA "dose" of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 9 OS SGA CEA versus NO CEA." data-id="CD002200-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 9 OS SGA CEA versus NO CEA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 10 OS CT versus no CT." data-id="CD002200-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 10 OS CT versus no CT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002200-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/urn:x-wiley:14651858:media:CD002200:CD002200-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_t/tCD002200-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 11 OS CT versus &lt; 2 or no CT." data-id="CD002200-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Intensive follow‐up versus minimalist follow‐up, Outcome 11 OS CT versus &lt; 2 or no CT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/media/CDSR/CD002200/image_n/nCD002200-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002200-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intensive follow‐up compared to less intensive follow‐up for patients treated for colorectal cancer with curative intent</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intensive follow‐up compared to less intensive follow‐up for patients treated for colorectal cancer with curative intent</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> people with non‐metastatic colorectal cancer treated with curative intent </p> <p><b>Setting:</b> primary and secondary care </p> <p><b>Interventions:</b> more intensive follow‐up (clinic visits and investigations aimed at detecting recurrence) </p> <p><b>Comparison:</b> less intensive follow‐up </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with less intensive follow‐up</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with intensive follow‐up</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/> Follow‐up: range 8 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>12,528<br/> (15 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/> (0.80 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 fewer per 1000<br/> (60 fewer to 9 more)<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Colorectal cancer‐specific survival</b><br/> Follow‐up: range 8 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>11,771<br/> (11 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/> (0.81 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 fewer per 1000<br/> (47 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Relapse‐free survival</b><br/> Follow‐up: range 48 months to 120 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>8047<br/> (16 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/> (0.92 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 more per 1000<br/> (30 fewer to 66 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Salvage surgery</b> (surgery at relapse with curative intent)<br/> Follow‐up: range 2 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5157<br/> (13 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.98<br/> (1.53 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 more per 1000<br/> (33 more to 96 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interval recurrences</b> (recurrence CRC diagnosed between scheduled follow‐up visits)<br/> Follow‐up: range 2 months to 134 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3933<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.59<br/> (0.41 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 fewer per 1000<br/> (75 fewer to 18 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Harms</b> </p> <p>Colonoscopy complications ‐ bowel perforation</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>326</p> <p>(1 RCT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very Low<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.83</p> <p>(0.36 to 131.21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 fewer per 1000<br/> (0 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>CRC:</b> colorectal cancer; <b>HR:</b> hazard ratio; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>OR:</b> Peto odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for imprecision because there were more than 300 events.<br/> <sup>b</sup>Confidence intervals include 1 and exclude clinically meaningful benefit or harm.<br/> <sup>c</sup>We used the number of events in the control arms of the included studies to derive absolute values.<br/> <sup>d</sup>Downgraded because we deemed 192/468 (41%) events from studies at high risk of bias because of incomplete follow‐up.<br/> <sup>e</sup>Not downgraded because prespecified sensitivity analysis explained heterogeneity on basis of study age.<br/> <sup>f</sup>Downgraded because we deemed 95/178 (58%) events from studies at high risk of bias because of incomplete follow‐up.<br/> <sup>g</sup>Downgraded for risk of bias related to lack of blinding and imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intensive follow‐up compared to less intensive follow‐up for patients treated for colorectal cancer with curative intent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002200-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>More intensive follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Less intensive follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Studies comparing more visits and tests versus fewer visits and tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0001" title='VerberneC , DoornbosPM , GrossmannI , DeBockGH , WiggersT . Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging. European Journal of Cancer. 2013; Vol. 49:S480. VerberneCJ , WiggersT , GrossmannI , deBockGH , VermeulenKM . Cost‐effectiveness of a carcinoembryonic antigen (CEA) based follow‐up programme for colorectal cancer (the CEA Watch trial). Colorectal Disease2016;18(3):O91‐o96. VerberneCJ , ZhanZ , DeBockG , WiggersT . Intensifying colorectal cancer follow‐up survival analysis of the randomized multicenter CEAwatch trial. European Journal of Surgical Oncology. 2016; Vol. 42:9 S106. VerberneCJ , ZhanZ , Van denHeuvelE , GrossmannI , DoornbosPM , HavengaK , et al. Intensified follow‐up in colorectal cancer patients using frequent carcino‐embryonic antigen (CEA) measurements and CEA‐triggered imaging: results of the randomized "CEAwatch" trial. European Journal of Surgical Oncology2015;41(9):1188‐96. VerberneCJ , ZhanZ , Van denHeuvelER , OppersF , DeJongAM , GrossmannI , et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. British Journal of Surgery2017;104(8):1069‐77. [DOI: 10.1002/bjs.10535] ZhanZ , Van denHeuvelER , DoornbosPM , BurgerH , VerberneCJ , WiggersT , et al. Strengths and weaknesses of a stepped wedge cluster randomized design: its application in a colorectal cancer follow‐up study. Journal of Clinical Epidemiology2014;67(4):454‐61. ZhanZ , VerberneCJ , Van denHauvelER , GrossmanI , RanchorAV , WiggersT , et al. Psychological effects of the intensified follow‐up of the CEAwatch trial after treatment for colorectal cancer. PLOS One2017;12(9):e0184740. [DOI: 10.1371/journal.pone.0184740] '>CEAwatch 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 2‐monthly year 1‐3, then 3‐monthly year 4‐5</p> <p>Clinic visits 12‐monthly year 1‐3</p> <p>CT CAP 12 monthly for 3 years</p> <p>CXR and liver US annually year 1‐3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 3‐6‐monthly year 1‐3, 12 monthly year 4‐5</p> <p>Clinic visits 6‐monthly year 1‐3, 12 monthly year 4‐5</p> <p>CXR and liver US 6‐monthly year 1‐3, 12‐monthly year 4‐5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0004" title='FossatiR , AndreoniA , DiCostanzoB , FossatiD , JohnsonG , LiberatiL , et al. Preliminary results of the Italian study "GILDA" [Preliminari dello studio I risultati preliminari dello studio italiano GILDA]. 2005. [3026272] GrossmannEM ,  JohnsonFE ,  VirgoKS ,  LongoWE ,  FossatiR . Follow‐up of colorectal cancer patients after resection with curative intent‐the GILDA trial. Surgical Oncology2004;13(2‐3):119‐24. JohnsonFE , VirgoKS , GrossmannEM , LongoWE , FossatiR . Colorectal cancer patient follow‐up following surgery with curative intent: the GILDA trial. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post‐meeting Edition)2004;22:14S. RosatiG , AmbrosiniG , BarniS , AndreoniB , CorradiniG , LuchenaG , et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2‐C colorectal carcinoma. Annals of Oncology2016;27(2):274‐80. [DOI: 10.1093/annonc/mdv541] '>GILDA 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Office visits at 4, 8, 12, 16, 20, 24, 30, 36, 42, 48, and 60 months and history and clinical examination, FBC, CEA, and CA 19‐9 </p> <p>Colonoscopy and CXR at 12, 24, 36, 48, and 60 months</p> <p>Liver US at 4, 8, 12, 16, 24, 36, 48, and 60 months</p> <p>For rectal participants, pelvic CT at 4, 12, 24, and 48 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Office visits at 4, 8, 12, 16, 20, 24, 30, 42, 48, and 60 months, including history, examination, and CEA </p> <p>Colonoscopy at 12 and 48 months</p> <p>Liver US at 4 and 16 months</p> <p>Rectal cancer participants in addition had rectoscopy at 4 months, CXR at 12 months, and liver US at 8 and 16 months. A single pelvic CT was allowed if a radiation oncologist required it as baseline following adjuvant treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0005" title="KjeldsenBJ , KronborgO , FengerC , JørgensenOD . A prospective randomised study of follow‐up after radical surgery for colorectal cancer. British Journal of Surgery1997;84(5):666‐9. KjeldsenBJ , KronborgO , FengerC , JørgensenOD . The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. International Journal of Colorectal Disease1997;12(6):329‐34. KjeldsenBJ , ThorsenH , WhalleyD , KronborgO . Influence of follow‐up on health‐related quality of life after radical surgery for colorectal cancer. Scandinavian Journal of Colorectal Diseases1999;34(5):509‐15. ">Kjeldsen 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits at 6, 12, 18, 30, 36, 48, 60, 120, 150, and 180 months after radical surgery<br/> Examinations included medical history, clinical examination, DRE, gynaecological examination, Haemoccult‐II test, colonoscopy, CXR, haemoglobin level, erythrocyte sedimentation rate, and liver enzymes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits at 60, 120, and 180 months</p> <p>Examinations included medical history, clinical examination, DRE, gynaecological examination, Haemoccult‐II test, colonoscopy, CXR, haemoglobin level, erythrocyte sedimentation rate, and liver enzymes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0006" title="MäkeläJ , LaitinenS , KairaluomaMI . Early results of follow‐up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. Surgical Oncology1992;1(2):157‐61. MäkeläJT , LaitinenSO , KairaluomaMI . Five‐year follow‐up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery1995;130(10):1062‐7. ">Mäkelä 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants with rectal or sigmoid cancers had flexible sigmoidoscopy with video imaging every 3 months, colonoscopy at 3 months (if it had not been done preoperation), then annually. Liver US and primary site at 6 months, then annually </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants who had rectal and sigmoid cancers had rigid sigmoidoscopy and barium enema annually </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0009" title="PietraN , SarliL , CostiR , OuchemiC , GrattarolaM , PeracchiaA . Role of follow‐up in management of local recurrences of colorectal cancer: a prospective, randomized study. Diseases of the Colon and Rectum1998;41(9):1127‐33. ">Pietra 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 months, then annually thereafter. </p> <p>At each visit: clinical examination, US, CEA, and CXR. Annual CT liver and colonoscopy were performed </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seen at 6 and 12 months, then annually.</p> <p>At each visit, clinical examination, CEA, and US were performed. They had annual CXR, yearly colonoscopy, and CT scan. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0010" title="BessaX , SalóJ , ArcusaA , ElizaldeJ , BoadasJ , AlentornE , et al. Effectiveness of postoperative follow‐up in patients with colorectal cancer to detect curable recurrences. Preliminary analysis of a multicenter, randomized controlled trial. Gastroenterology and Hepatology. 2001; Vol. 24:2. Rodríguez‐MorantaF , SalóJ , ArcusaA , BoadasJ , PiñolV , BessaX , et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology2006;24(3):386‐93. ">Rodríguez‐Moranta 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>History, examination, and bloods (including CEA), US/CT, CXR, and colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>history, examination, and bloods (including CEA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0013" title="SobhaniI , TiretE , LabtahiR , AparicioT , IttiE , MontraversF , et al. Early detection of recurrence by 18FDG‐PET in the follow‐up of patients with colorectal cancer. British Journal of Cancer2008;98(5):875‐80. ">Sobhani 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PET performed at 9 and 15 months and conventional follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0014" title="NCT00624260 . Impact of PET scan on the curative strategy of colo‐rectal cancers : a randomized study (ITEP). clinicaltrials.gov/ct2/show/record/NCT00624260?term=NCT00624260&amp;rank=1 (accessed 27 May 2018). SobhaniI , BaumgaertnerI , TounigandC , EtteE , BrunettiF , GagniereC , et al. option19 Follow‐up of colorectal cancer (CRC) patients including 18FDGPET‐CT (PET‐CT): an open‐label multicenter randomized trial (clinical trial: NCT 00624260). United European Gastroenterology Journal. 2017; Vol. 5:S1 A13. SobhaniI , BaumgaertnerI , IttiE , LucianiA , LayeseR , NatellaPA , et al. Colorectal cancer (CRC) patients surveyed by 18FDGPET‐CT (PET‐CT): an open label multicenter randomized trial (NCT 00624260). Journal of Clinical Oncology. 2018; Vol. 35:15S1. SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) Monitoring by Six‐Monthly 18 FDG‐PET/CT: An Open‐Label Multicientre Randomised Trial. Annals of Oncology2018;29(4):931‐937. [DOI: 10.1093/annonc/mdy031] SobhaniI , IttiE , BaumgaertnerI , LayeseR , AndreT , DucreuxM , et al. Colorectal cancer (CRC) monitering by six‐monthly 18. academic‐oup‐com.ezproxy.library.uq.edu.au/annonc/article/29/4/931/4819113#supplementary‐data (accessed 20 June 2018)2018; Vol. 29, issue 4. ">Sobhani 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FDG PET/CT at 6, 12, 18, 24, 30 and 36 months pus conventional follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional follow‐up: physical examination and laboratory tests (FBC, tumour markers) at 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 months, liver US and CXR at 3, 9, 15, 21, 27, 33 months, CT CAP at 6, 12, 18, 24, 30 and 36 months, colonoscopy at 12 and 36 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0016" title="JeffordM , ArandaS , GoughK , Lotfi‐JamK , ButowP , KrishnasamyM , et al. Evaluating a nurse‐led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials2013;14(1):260. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowP , et al. A randomized controlled trial of a nurse‐led supportive care package (SurvivorCare) for survivors of colorectal cancer. Oncologist2016;21(8):1014‐23. JeffordM , GoughK , DrosdowskyA , RussellL , ArandaS , ButowPN , et al. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC). Journal of Clinical Oncology2016;34(3):3S1. ">SurvivorCare 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse‐led survivorship care package:</p> <p> <ol id="CD002200-list-0021"> <li> <p>educational materials</p> </li> <li> <p>needs assessment</p> </li> <li> <p>survivorship care plan</p> </li> <li> <p>end‐of‐treatment session</p> </li> <li> <p>3 follow‐up phone calls plus usual care</p> </li> </ol> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care defined as: "care according to the treating cancer centre or practitioner's usual practice" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002200-bbs2-0017" title="ISRCTN76694943 . A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second‐look surgery in recurrent colorectal cancer. www.isrctn.com/ISRCTN76694943?q=&amp;filters=&amp;sort=&amp;offset=14345&amp;totalResults=14626&amp;page=287&amp;pageSize=50&amp;searchType=basic‐search (accessed 6 April 2019). LennonT , HoughtonJ , NorthoverJ , on behalf of CRC/NIH CEA Trial Working Party. Post‐operative CEA monitoring and second‐look surgery in colorectal cancer: trial results. British Journal of Cancer. Proceedings of Ninth Annual Scientific Meeting of the British Oncological Association. New Jersey: Macmillan Publishers Ltd, 1994:16. NorthoverJ , HoughtonJ , LennonT . CEA to detect recurrence of colon cancer. JAMA1994;272(1):31. TreasureT , MonsonK , FiorentinoF , RussellC . The CEA Second‐Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ open2014;4(5):e004385. [DOI: 10.1.1136/bmjopen‐2013‐004385] ">Treasure 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA rise triggered 'second‐look' surgery, with intention to remove any recurrence discovered </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA rise did not trigger 'second‐look' surgery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0018" title="WangT , CuiY , HuangWS , DengYH , GongW , LiCJ , et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointestinal Endoscopy2009;69(3 Pt 2):609‐15. ">Wang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colonoscopy at each visit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colonoscopy at 6 months, 30 months, and 60 months from randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Studies comparing tests and visits with minimal or no follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0002" title="HansdotterP , Wille‐Jørgensen , Horváth‐PuhóE , PetersenSH , MartlingA , SørensonHT . The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clinical Epidemiology2016;8:15‐21. NCT00225641 . Assessment of frequency of surveillance after curative resection in patients with stage II and III colorectal cancer [COLOFOL ‐ a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer ‐ a randomised multicentre trial]. clinicaltrials.gov/ct2/show/NCT00225641?term=NCT00225641&amp;rank=1 (first received 14 November 2012). Wille‐JorgensenP , SykI , SmedhK , LaurbergS , NielsenDT , PetersenSH , et al. Effect of more vs less frequent follow‐up testing on overall and colorectal cancer‐specific survival mortality in patients with stage II or III colorectal cancer. The COLFOL randomized clinical trial. JAMA2018;319(20):2095‐103. Wille‐JørgensenP , LaurbergS , PåhlmanL , CarriquiryL , LundqvistN , SmedhK , et al. An interim analysis of recruitment to the COLOFOL trial. Colorectal Disease2009;11(7):756‐8. Wille‐JørgensenP , LaurbergS , Toft SørensenH , PåhlmanL , on behalf of the COLOFOL study group. COLOFOL study protocol a pragmatic study to assess the frequency of surveillance tests after curative resection in patients with stage II and III colorectal cancer– a randomised multicentre trial. www.colofol.com/html/download/COLOFOL_7‐5.pdf (accessed 30 April 2008). ">COLOFOL 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 1 month postoperatively then CEA, CT chest and abdomen 6, 12, 18, 24, and 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CEA 1 month postoperatively then CEA, CT chest and abdomen 12 and 36 months after surgery </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0003" title="CorkhillA , PrimroseJN , MantD , The FACS Study Group. Follow up after colorectal cancer (the FACS trial). British Journal of Cancer2004;91(Suppl 1):S78. MantD , GrayA , PughS , CampbellH , GeorgeS , FullerA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent. Health Technology Assessment2017; Vol. 21, issue 32. [DOI: 10.3310/hta21320] MantD , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3‐5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. 2013; Vol. 31S:3500. NCT00560365 . Follow‐up study of patients who have undergone surgery for stage I, stage II, or stage III colorectal cancer [A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (FACS ‐ Follow‐up After Colorectal Surgery)]. clinicaltrials.gov/ct2/show/NCT00560365?term=NCT00560365&amp;rank=1 (first received 14 November 2012). PrimroseJ , MantD , RoseP , GeorgeS , NugentK , GrayA , et al. A randomised controlled trial to assess the cost‐effectiveness of intensive versus no scheduled follow‐up in patients who have undergone resection for colorectal cancer with curative intent (The FACS Trial). www.nets.nihr.ac.uk/projects/hta/991099. Winchester: John Wiley &amp; Sons, Ltd., (accessed 23 July 2018). PrimroseJN , FullerA , RoseP , Perera‐SalazarR , MellorJ , CorkhillA , et al. Follow‐up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts Part 12011;29, No 15(Suppl (May 20)):3521. PrimroseJN , PereraR , GrayA . Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Diseases of the Colon and Rectum2014;57:e421‐2. PrimroseJN , PereraR , GrayA , RoseP , FullerA , CorkhillA , et al. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA2014;311(3):263‐70. PrimroseJN , PereraR , GrayA , et al. FACS Trial Investigators. Supplementary Online Content. Effect of 3 to 5 years of scheduled CEA and CT follow‐up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. cdn.jamanetwork.com/ama/content_public/journal/jama/929670/joi130124supp1_prod.pdf?Expires=2147483647&amp;Signature=tqyZRUZOZ3TvJrZ2‐4iAyWuXfpwCyW6kMQChZEFbH6˜NvVywPoTOsHcY9POszrRepxg˜7n˜FIzHUIhSz4yTen‐CqgWp0xYUlfJ˜VwEheI24XC00OX9x9eM3NaTrfnrXIjSFu‐TPHuevJ1fyp8UyLkFLFxQ2mnFaP1PzOSnH‐twxhWsyS6iIL9‐Kuza7G70XLwnAwQk‐CkWyOxSgXmxBTW1Hwdihn8BsAJpCWTdPD7HoK1CcUb5uCUMozUTHxRyXOvL˜oQJZy78j˜QxigPperxRFqctIyYEomfj9Y3vsgcWVcLeoORQvGWhHlvMUZpbm2AJ4ivAT0xVWkR‐7pKOBsfg__&amp;Key‐Pair‐Id=APKAIE5G5CRDK6RD3PGA (accessed 10th August 2019). PughSA . Site and stage of colorectal cancer influences the likelihood and distribution of disease recurrence and post‐recurrence cancer survival. Data from FACS randomised controlled trial. Annals of Surgery2016;263(6):1143. PughSA , MantB , ShinkinsB , MellorR , PerreraR , PrimroseJ . Scheduled use of CEA and CT follow‐up to detect recurrence of colorectal cancer: 6‐12 year results from the FACS randomised controlled trial. Annals of Oncology. 2016; Vol. 27:S6. ReibetanzJ , GermerCT . Influence of structured CEA determination and CT‐scan to detect recurrence of colorectal cancer: results of the randomized clinical FACS study. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen2014;85(7):642. ShinkinsB , NicholsonBD , JamesT , PathirajaI , PughS , PereraR , et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow‐up? A systematic review and secondary analysis of a randomised controlled trial. Health Technology Assessment2017; Vol. 21, issue 32:1‐60. ShinkinsB , PrimroseJN , PughSA , NicholsonBD , PereraR , JamesT , et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. British Journal of Surgery2018;6:658‐62. ShrinkinsB , NicholsonBD , PrimroseJ , PereraR , JamesRT , PughS , et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS One2017; Vol. 12, issue 3:e0171810. ">FACS 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD002200-list-0022"> <li> <p>CEA testing every 3 months for 2 years, then every 6 months for 3 years with a single CT scan of the CAP if requested at study entry by clinician </p> </li> <li> <p>CT scan of the CAP every 6 months for 2 years, then annually for 3 years, plus colonoscopy at 2 years </p> </li> <li> <p>CEA and CT follow‐up: both blood and imaging as above, plus colonoscopy at 2 years</p> </li> </ol> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No scheduled follow‐up except a single CT scan of the CAP if requested at study entry by a clinician </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0007" title="KronborgO , FengerC , DeichgräberE , HansenL . Follow‐up after radical surgery for colorectal cancer. Design of a randomized study. Scandinavian Journal of Gastroenterology1988;23(Suppl 149):159‐62. OhlssonB , BrelandU , EkbergH , GraffnerH , TranbergKG . Follow‐up after curative surgery for colorectal carcinoma. Randomized comparison with no follow‐up. Diseases of the Colon and Rectum1995;38(6):619‐26. ">Ohlsson 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐, 6‐, 9‐, 12‐, 15‐, 18‐, 21‐, 24‐, 30‐, 36‐, 42‐, 48‐, and 60‐month clinic visits. Performed at each visit were clinical exam, rigid proctosigmoidoscopy, CEA, alkaline phosphatase, gamma‐glutaryl transferase, faecal haemoglobin, and CXR. Examination of anastomosis (flexible sigmoidoscopy or colonoscopy, as dictated by the lesion) was performed at 9, 21, and 42 months. Colonoscopy was performed at 3, 15, 30, and 60 months. CT of the pelvis was performed at 3, 6, 12, 18, and 24 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No planned follow‐up visits. Participants received written instructions recommending that they leave faecal samples with the district nurse for examination every third month during the first 2 years after surgery then once a year. They were instructed to contact the surgical department if they had any symptoms. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0011" title="SchoemakerD , BlackR , GilesL , ToouliJ . Yearly colonoscopy, liver CT, and chest radiography do not influence 5‐year survival of colorectal cancer patients. Gasteroenterology1998;114(1):7‐14. ">Schoemaker 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yearly CXR, CT of the liver, and colonoscopy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These investigations were only performed in the control group if indicated on clinical grounds or after screening test abnormality, and at 5 years of follow‐up, to exclude a reservoir of undetected recurrences </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0012" title="SeccoGB , FardelliR , GianquintoD , BonfanteP , BaldiE , RaveraG , et al. Efficacy and cost of risk adapted follow‐up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. European Journal of Surgical Oncology2002;28(4):418‐23. ">Secco 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinic visits and serum CEA, abdomen/pelvic US scans, and CXR. Participants with rectal carcinoma had rigid sigmoidoscopy and CXR. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"minimal follow‐up programme performed by physicians"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Studies that assessed effect of setting for follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0008" title="AugestadKM , NorumJ , DehofS , AspevikR , RingbergU , NestvoldT , et al. Cost‐effectiveness and quality of life in surgeon versus general practitioner‐organised colon cancer surveillance: a randomised controlled trial. BMJ Open2013;3(4):e002391. [NCT00572143] AugestadKM , NorumJ , RoseJ , LindsetmoRO . A prospective analysis of false positive events in a National Colon Cancer Surveillance Program. BMC Health Services Research2014;14:137. [DOI: 10.1186/1472‐6963‐14‐137] AugestadKM , VonenB , AspevikR , NestvoldT , RingbergU , JohnsenR , et al. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost‐effectiveness and serious clinical events. BMC Health Services Research2008;8:137. NCT00572143 . Follow‐up after surgery for colon cancer. General practice vs. surgical‐based follow‐up? (ONKOLINK). clinicaltrials.gov/ct2/show/NCT00572143?term=follow‐up&amp;type=Intr&amp;cond=Colorectal+Cancer&amp;rank=6 (accessed 9 Janury 2019). ">ONCOLINK</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgeon‐led follow‐up</p> <p>Frequency of follow‐up equal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GP‐led follow‐up</p> <p>Frequency of follow‐up equal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0015" title="StrandE , NygrenI , BergkvistL , SmedhK . Nurse or surgeon follow‐up after rectal cancer: a randomized trial. Colorectal Disease2011;13(9):999‐1003. ">Strand 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgeon‐led follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nurse‐led follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0019" title="WattchowDA , WellerD , PilottoL , EstermannA . Randomized controlled trial (RCT) comparing hospital and general practice based follow‐up of patients with colon cancer. Australian and New Zealand Journal of Surgery2002;72 Suppl:A22. WattchowDA , WellerDP , EstermanA , PilottoLS , McGormK , HammettZ , et al. General practice vs surgical‐based follow‐up for patients with colon cancer: randomised controlled trial. British Journal of Cancer2006;94(8):1116‐21. ">Wattchow 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary care setting and environment for follow‐up<br/> Follow‐up guidance was based on current clinical practice, and guidance was provided that suggested follow‐up visits every 3 months for the first 2 years postoperatively, then every 6 months for the next 3 years.<br/> Each visit incorporated asking a list of set questions about symptoms, physical examination, annual faecal occult blood testing, and colonoscopy every 3 years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary care setting for follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>CA 19‐9:</b> cancer antigen 19‐9; <b>CEA:</b> carcinoembryonic antigen; <b>CAP:</b> chest, abdomen, pelvis; <b>CT:</b> computed tomography; <b>CXR:</b> chest X‐ray; <b>DRE:</b> digital rectal examination; <b>FBC:</b> full blood count; <b>FDG:</b> fluorodeoxyglucose; <b>PET:</b> positron emission tomography; <b>US:</b> ultrasound </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Interventions in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002200-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Systematic reviews on topic</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies included</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Search date</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes for overall survival for comparison intensive versus less intensive follow‐up for participants treated with curative intent for colorectal cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0041" title="AugestadKM , RoseJ , CrawhsawB , CooperG , DelaneyC . Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review. World Journal of Gastrointestinal Oncology2014;6(5):104‐11. ">Augestad 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No search date given</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not present quantitative meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0042" title="BacaB , BeartRW , EtzioniDA . Surveillance after colorectal cancer resection: a systematic review. Diseases of the Colon and Rectum2011;54(8):1036‐48. ">Baca 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>January 2000 to 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did not present quantitative meta‐analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002200-bbs2-0080" title="Pita‐FernándezS , Alhayek‐AíM , González‐MartinC , López‐CalviñoB , Seoane‐PilladoT , Pértega‐DíazS . Intensive follow‐up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta‐analysis. Annals of Oncology Advance Access2014;00:1‐12. ">Pita‐Fernández 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>June 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.75 (95% CI 0.66 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002200-bbs2-0082" title="RenehanA , EggerM , SaundersMP , O'DwyerST . Impact on survival of intensive follow‐up after curative resection for colorectal cancer: systematic review and meta‐analysis of randomised trials. BMJ2002;324:813. ">Renehan 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>April 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.81 (95% CI 0.70 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002200-bbs2-0094" title="TjandraJJ , ChanMK . Follow‐up after curative resection of colorectal cancer: a meta‐analysis. Diseases of the Colon and Rectum2007;50(11):1783‐99. ">Tjandra 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74 (95% CI 0.59 to 0.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>OR:</b> odds ratio; RR: risk ratio </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Systematic reviews on topic</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/full#CD002200-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002200-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intensive follow‐up versus minimalist follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Colorectal cancer‐specific survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Relapse‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.92, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Salvage surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.53, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Interval recurrences <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.41, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Harms (colonoscopic complications) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.30 [0.75, 70.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Overall survival SG Healthcare professional <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Community</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.38, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.80, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Overall survival SGA "dose" of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 More visits and tests versus fewer visits and tests</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 VIsits and tests versus minimal or no follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 OS SGA CEA versus NO CEA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.79, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 No CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.67, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 OS CT versus no CT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 No CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.40, 4.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 OS CT versus &lt; 2 or no CT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.65, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 &lt; 2 or no CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.70, 1.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intensive follow‐up versus minimalist follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002200.pub4/references#CD002200-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002200.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002200-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002200-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002200-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002200-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD002200-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002200-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD002200-note-0015">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD002200-note-0014">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002200-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002200-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002200\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002200\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002200\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002200\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002200\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002200.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002200.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002200.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002200.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002200.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719232771"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002200.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719232775"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002200.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de3bc9ad39368',t:'MTc0MDcxOTIzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 